Gene	O
transfer	O
of	O
antisense	O
hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
alpha	I-protein
enhances	O
the	O
therapeutic	O
efficacy	O
of	O
cancer	O
immunotherapy	O
.	O

Solid	O
tumors	O
meet	O
their	O
demands	O
for	O
nascent	O
blood	O
vessels	O
and	O
increased	O
glycolysis	O
,	O
to	O
combat	O
hypoxia	O
,	O
by	O
activating	O
multiple	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
glucose	O
metabolism	O
.	O

Hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
(	O
HIF-1	B-protein
)	O
is	O
a	O
constitutively	O
expressed	O
basic	O
helix-loop-helix	B-protein
transcription	I-protein
factor	I-protein
,	O
formed	O
by	O
the	O
assembly	O
of	O
HIF-1alpha	B-protein
and	O
HIF-1beta	B-protein
(	O
Arnt	B-protein
)	O
,	O
that	O
is	O
stablized	O
in	O
response	O
to	O
hypoxia	O
,	O
and	O
rapidly	O
degraded	O
under	O
normoxic	O
conditions	O
.	O

It	O
activates	O
the	O
transcription	O
of	O
genes	O
important	O
for	O
maintaining	O
oxygen	O
homeostasis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	O
HIF-1alpha	B-protein
by	O
intratumoral	O
gene	O
transfer	O
of	O
an	O
antisense	B-DNA
HIF-1alpha	I-DNA
plasmid	I-DNA
leads	O
to	O
the	O
down-regulation	O
of	O
VEGF	B-DNA
,	O
and	O
decreased	O
tumor	O
microvessel	O
density	O
.	O

Antisense	O
HIF-1alpha	O
monotherapy	O
resulted	O
in	O
the	O
complete	O
and	O
permanent	O
rejection	O
of	O
small	O
(	O
0.1	O
cm	O
in	O
diameter	O
)	O
EL-4	O
tumors	O
,	O
which	O
is	O
unusual	O
for	O
an	O
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	O
tumor	O
growth	O
is	O
the	O
norm	O
.	O

It	O
induced	O
NK	B-cell_type
cell	I-cell_type
-dependent	O
rejection	O
of	O
tumors	O
,	O
but	O
failed	O
to	O
stimulate	O
systemic	O
T	B-cell_type
cell	I-cell_type
-mediated	O
anti-tumor	O
immunity	O
,	O
and	O
synergized	O
with	O
B7-1-mediated	O
immunotherapy	O
to	O
cause	O
the	O
NK	B-cell_type
cell	I-cell_type
and	O
CD8	B-cell_type
T	I-cell_type
cell	I-cell_type
-dependent	O
rejection	O
of	O
larger	O
EL-4	O
tumors	O
(	O
0.4	O
cm	O
in	O
diameter	O
)	O
that	O
were	O
refractory	O
to	O
monotherapies	O
.	O

Mice	O
cured	O
of	O
their	O
tumors	O
by	O
combination	O
therapy	O
resisted	O
a	O
rechallenge	O
with	O
parental	B-cell_type
tumor	I-cell_type
cells	I-cell_type
,	O
indicating	O
systemic	O
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O

In	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	O
progress	O
to	O
target	O
the	O
many	O
HIF-1	B-protein
effectors	O
,	O
the	O
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	O
pathways	O
and	O
enhancing	O
NK-mediated	O
antitumor	O
immunity	O
by	O
targeting	O
HIF-1	B-protein
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	O
cancer	O
immunotherapy	O
.	O

Gene	NULL
Therapy	NULL
(	NULL
2001	NULL
)	NULL
8	NULL
,	NULL
638-645	NULL
©	NULL
2001	NULL
Nature	NULL
Publishing	NULL
Group	NULL
All	NULL
rights	NULL
reserved	NULL
0969-7128/01	NULL
$	NULL
15.00	NULL
www.nature.com/gt	NULL
RESEARCH	NULL
ARTICLE	NULL
Gene	NULL
transfer	NULL
of	NULL
antisense	NULL
hypoxia	NULL
inducible	NULL
factor-1	NULL
a	NULL
enhances	NULL
the	NULL
therapeutic	NULL
efficacy	NULL
of	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
``	NULL
?	NULL

,	NULL
JR	NULL
Kanwar	NULL
'	NULL
,	NULL
E	NULL
Leung	NULL
``	NULL
,	NULL
K.	NULL
Lehnert	NULL
'	NULL
,	NULL
D	NULL
Wang	NULL
'	NULL
and	NULL
GW	NULL
Krissansen	NULL
'	NULL
'Division	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
and	NULL
Health	NULL
Science	NULL
,	NULL
University	NULL
of	NULL
Auckland	NULL
,	NULL
Auckland	NULL
,	NULL
New	NULL
Zealand	NULL
;	NULL
and	NULL
*Department	NULL
of	NULL
Surgery	NULL
,	NULL
Affiliated	NULL
Hospital	NULL
of	NULL
Shandong	NULL
Medical	NULL
University	NULL
,	NULL
Jinan	NULL
,	NULL
Shandong	NULL
Province	NULL
,	NULL
PR	NULL
China	NULL
Solid	NULL
tumors	NULL
meet	NULL
their	NULL
demands	NULL
for	NULL
nascent	NULL
blood	NULL
vessels	NULL
and	NULL
increased	NULL
glycolysis	NULL
,	NULL
to	NULL
combat	NULL
hypoxia	NULL
,	NULL
by	NULL
activating	NULL
multiple	NULL
genes	NULL
involved	NULL
in	NULL
angiogenesis	NULL
and	NULL
glucose	NULL
metab-olism	NULL
.	NULL

Hypoxia	NULL
inducible	NULL
factor-1	NULL
(	NULL
HIF-1	NULL
)	NULL
is	NULL
a	NULL
constitutively	NULL
expressed	NULL
basic	NULL
helix-loop-helix	NULL
transcription	NULL
factor	NULL
,	NULL
formed	NULL
by	NULL
the	NULL
assembly	NULL
of	NULL
HIF-1	NULL
«	NULL
and	NULL
HIF-1B	NULL
(	NULL
Arnt	NULL
)	NULL
,	NULL
that	NULL
is	NULL
stab-lized	NULL
in	NULL
response	NULL
to	NULL
hypoxia	NULL
,	NULL
and	NULL
rapidly	NULL
degraded	NULL
under	NULL
normoxic	NULL
conditions	NULL
.	NULL

It	NULL
activates	NULL
the	NULL
transcription	NULL
of	NULL
genes	NULL
important	NULL
for	NULL
maintaining	NULL
oxygen	NULL
homeostasis	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
engineered	NULL
down-regulation	NULL
of	NULL
HIF-1	NULL
«	NULL
by	NULL
intratumoral	NULL
gene	NULL
transfer	NULL
of	NULL
an	NULL
antisense	NULL
HIF-1	NULL
«	NULL
plasmid	NULL
leads	NULL
to	NULL
the	NULL
down-regulation	NULL
of	NULL
VEGF	NULL
,	NULL
and	NULL
decreased	NULL
tumor	NULL
microvessel	NULL
density	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
-	NULL
monotherapy	NULL
resulted	NULL
in	NULL
the	NULL
complete	NULL
and	NULL
permanent	NULL
rejection	NULL
of	NULL
small	NULL
(	NULL
0.1	NULL
cm	NULL
in	NULL
diameter	NULL
)	NULL
EL-4	NULL
tumors	NULL
,	NULL
which	NULL
is	NULL
unusual	NULL
for	NULL
an	NULL
anti-angiogenic	NULL
agent	NULL
where	NULL
transient	NULL
suppression	NULL
of	NULL
tumor	NULL
growth	NULL
is	NULL
the	NULL
norm	NULL
.	NULL

It	NULL
induced	NULL
NK	NULL
cell-dependent	NULL
rejection	NULL
of	NULL
tumors	NULL
,	NULL
but	NULL
failed	NULL
to	NULL
stimulate	NULL
systemic	NULL
T	NULL
cell-mediated	NULL
anti-tumor	NULL
immunity	NULL
,	NULL
and	NULL
synergized	NULL
with	NULL
B7-1-mediated	NULL
immunotherapy	NULL
to	NULL
cause	NULL
the	NULL
NK	NULL
cell	NULL
and	NULL
CD8	NULL
T	NULL
cell-dependent	NULL
rejection	NULL
of	NULL
larger	NULL
EL-4	NULL
tumors	NULL
(	NULL
0.4	NULL
cm	NULL
in	NULL
diameter	NULL
)	NULL
that	NULL
were	NULL
refractory	NULL
to	NULL
monotherapies	NULL
.	NULL

Mice	NULL
cured	NULL
of	NULL
their	NULL
tumors	NULL
by	NULL
combination	NULL
therapy	NULL
resisted	NULL
a	NULL
rechallenge	NULL
with	NULL
parental	NULL
tumor	NULL
cells	NULL
,	NULL
indicating	NULL
systemic	NULL
antitumor	NULL
immunity	NULL
had	NULL
been	NULL
achieved	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
whilst	NULL
intensive	NULL
investigations	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
target	NULL
the	NULL
many	NULL
HIF-1	NULL
effectors	NULL
,	NULL
the	NULL
results	NULL
herein	NULL
indicate	NULL
that	NULL
blocking	NULL
hypoxia-inducible	NULL
pathways	NULL
and	NULL
enhancing	NULL
NK-mediated	NULL
antitumor	NULL
immunity	NULL
by	NULL
targeting	NULL
HIF-1	NULL
itself	NULL
may	NULL
be	NULL
advantageous	NULL
,	NULL
especially	NULL
when	NULL
combined	NULL
with	NULL
cancer	NULL
immunotherapy	NULL
.	NULL

Gene	NULL
Therapy	NULL
(	NULL
2001	NULL
)	NULL
8	NULL
,	NULL
638-645	NULL
.	NULL

Keywords	NULL
:	NULL
cancer	NULL
gene	NULL
therapy	NULL
;	NULL
cancer	NULL
;	NULL
hypoxia	NULL
inducible	NULL
factor-1	NULL
«	NULL
;	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor	NULL
;	NULL
angiogenesis	NULL
;	NULL
immunotherapy	NULL
Introduction	NULL
Solid	NULL
tumors	NULL
must	NULL
establish	NULL
a	NULL
blood	NULL
supply	NULL
and/or	NULL
display	NULL
enhanced	NULL
glucose	NULL
metabolism	NULL
to	NULL
grow	NULL
beyond	NULL
a	NULL
few	NULL
mm	NULL
.	NULL
'	NULL

How	NULL
they	NULL
sense	NULL
hypoxia	NULL
,	NULL
and	NULL
respond	NULL
by	NULL
activating	NULL
hypoxia-inducible	NULL
genes	NULL
and	NULL
secreting	NULL
angiogenic	NULL
factors	NULL
to	NULL
establish	NULL
a	NULL
blood	NULL
system	NULL
is	NULL
central	NULL
to	NULL
cancer	NULL
biology	NULL
,	NULL
the	NULL
answers	NULL
to	NULL
which	NULL
will	NULL
provide	NULL
new	NULL
strategies	NULL
for	NULL
cancer	NULL
treatment	NULL
.	NULL
``	NULL

''	NULL
Many	NULL
tumors	NULL
contain	NULL
hypoxic	NULL
microen-vironments	NULL
,	NULL
which	NULL
have	NULL
been	NULL
associated	NULL
with	NULL
malignant	NULL
progression	NULL
,	NULL
poor	NULL
prognosis	NULL
,	NULL
metastasis	NULL
and	NULL
resistance	NULL
to	NULL
radiotherapy	NULL
and	NULL
chemotherapy	NULL
.	NULL

'*	NULL
``	NULL
The	NULL
discovery	NULL
of	NULL
hypoxia-inducible	NULL
factor-1	NULL
(	NULL
HIF-1	NULL
)	NULL
gave	NULL
an	NULL
insight	NULL
into	NULL
the	NULL
regulation	NULL
of	NULL
hypoxia-inducible	NULL
genes	NULL
.	NULL

``	NULL
**	NULL
HIF-1	NULL
,	NULL
which	NULL
is	NULL
formed	NULL
by	NULL
the	NULL
assembly	NULL
of	NULL
HIF-1	NULL
«	NULL
and	NULL
HIF-1B	NULL
(	NULL
Arnt	NULL
)	NULL
during	NULL
binds	NULL
hypoxia-response	NULL
elements	NULL
(	NULL
HREs	NULL
)	NULL
in	NULL
enhancers	NULL
of	NULL
genes	NULL
encoding	NULL
angiogenic	NULL
factors	NULL
such	NULL
as	NULL
VEGF	NULL
,	NULL
and	NULL
glycoly-sis-related	NULL
proteins	NULL
such	NULL
as	NULL
glycolytic	NULL
enzymes	NULL
,	NULL
and	NULL
glucose	NULL
transporters	NULL
1	NULL
and	NULL
3	NULL
(	NULL
Glut-1	NULL
and	NULL
3	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
Correspondence	NULL
:	NULL
GW	NULL
Krissansen	NULL
,	NULL
Department	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
School	NULL
of	NULL
Medicine	NULL
and	NULL
Health	NULL
Science	NULL
,	NULL
University	NULL
of	NULL
Auckland	NULL
,	NULL
Auckland	NULL
,	NULL
New	NULL
Zealand	NULL
Received	NULL
5	NULL
July	NULL
2000	NULL
;	NULL
accepted	NULL
22	NULL
November	NULL
2000	NULL
proteins	NULL
are	NULL
required	NULL
for	NULL
the	NULL
high	NULL
glycolytic	NULL
rates	NULL
of	NULL
cancer	NULL
cells	NULL
,	NULL
and	NULL
hence	NULL
are	NULL
important	NULL
for	NULL
the	NULL
bioenergetics	NULL
of	NULL
tumor	NULL
growth	NULL
.	NULL

HIF-l1a	NULL
«	NULL
-deficiency	NULL
is	NULL
embryonically	NULL
lethal	NULL
resulting	NULL
from	NULL
impaired	NULL
vascularization	NULL
.	NULL
``	NULL

Embryonic	NULL
stem	NULL
cells	NULL
lacking	NULL
HIF-1	NULL
«	NULL
are	NULL
unable	NULL
to	NULL
up-regulate	NULL
several	NULL
HIF-1	NULL
target	NULL
genes	NULL
under	NULL
hypoxic	NULL
or	NULL
low	NULL
glucose	NULL
conditions	NULL
,	NULL
in	NULL
particular	NULL
enzymes	NULL
in	NULL
the	NULL
glycolytic	NULL
path-way	NULL
.	NULL
``	NULL

''	NULL
Loss	NULL
of	NULL
HIF-l	NULL
«	NULL
results	NULL
in	NULL
reduced	NULL
hypoxia-inducible	NULL
expression	NULL
of	NULL
VEGF	NULL
,	NULL
failure	NULL
to	NULL
form	NULL
new	NULL
blood	NULL
vessels	NULL
,	NULL
and	NULL
retardation	NULL
of	NULL
solid	NULL
tumor	NULL
growth	NULL
,	NULL
``	NULL
``	NULL
and	NULL
conversely	NULL
overexpression	NULL
correlates	NULL
with	NULL
tumor	NULL
growth	NULL
.	NULL
``	NULL

''	NULL
HIF-1	NULL
«	NULL
is	NULL
overexpressed	NULL
in	NULL
many	NULL
tumor	NULL
types	NULL
compared	NULL
with	NULL
respective	NULL
normal	NULL
tissues	NULL
,	NULL
including	NULL
colon	NULL
,	NULL
breast	NULL
,	NULL
gastric	NULL
,	NULL
lung	NULL
,	NULL
skin	NULL
,	NULL
ovarian	NULL
,	NULL
pancreatic	NULL
,	NULL
prostate	NULL
and	NULL
renal	NULL
carcinomas	NULL
.	NULL
``	NULL

''	NULL
Whereas	NULL
HIF-1	NULL
$	NULL
B	NULL
is	NULL
constitutively	NULL
expressed	NULL
,	NULL
HIF-l	NULL
«	NULL
is	NULL
rapidly	NULL
degraded	NULL
during	NULL
normoxia	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
,	NULL
and	NULL
dramatically	NULL
stabilized	NULL
and	NULL
activated	NULL
following	NULL
hypoxia	NULL
,	NULL
by	NULL
an	NULL
oxygen-sensing	NULL
and	NULL
signalling	NULL
process	NULL
that	NULL
remains	NULL
an	NULL
enigma	NULL
.	NULL
``	NULL

HIF-l	NULL
«	NULL
associates	NULL
with	NULL
pVHL	NULL
(	NULL
von	NULL
Hippel-Lindau	NULL
tumor-suppressor	NULL
protein	NULL
)	NULL
,	NULL
``	NULL
``	NULL
``	NULL
``	NULL
and	NULL
heat	NULL
shock	NULL
protein	NULL
90	NULL
that	NULL
determine	NULL
its	NULL
fate	NULL
.	NULL

pVHL	NULL
targets	NULL
hypoxia-inducible	NULL
factors	NULL
including	NULL
HIF-l1	NULL
«	NULL
for	NULL
oxygen-dependent	NULL
proteo-lysis	NULL
,	NULL
and	NULL
destabilizes	NULL
VEGF	NULL
and	NULL
other	NULL
hypoxically	NULL
regu-	NULL
lated	NULL
mRNAs	NULL
.	NULL
``	NULL

In	NULL
VHL-defective	NULL
cells	NULL
,	NULL
HIF-l	NULL
«	NULL
is	NULL
constitutively	NULL
stabilized	NULL
and	NULL
activated	NULL
,	NULL
``	NULL
resulting	NULL
in	NULL
inherited	NULL
hypervascular	NULL
tumors	NULL
.	NULL
``	NULL

Downstream	NULL
effectors	NULL
of	NULL
HIF-1	NULL
,	NULL
in	NULL
particular	NULL
VEGF	NULL
,	NULL
have	NULL
been	NULL
intensively	NULL
investigated	NULL
as	NULL
targets	NULL
for	NULL
the	NULL
treatment	NULL
of	NULL
solid	NULL
vascular	NULL
tumors	NULL
,	NULL
with	NULL
some	NULL
degree	NULL
of	NULL
suc-cess	NULL
.	NULL

Thus	NULL
inhibition	NULL
of	NULL
VEGF	NULL
expression	NULL
in	NULL
tumor	NULL
xenografts	NULL
leads	NULL
to	NULL
vascular	NULL
regression	NULL
,	NULL
and	NULL
decreased	NULL
tumor	NULL
growth	NULL
.	NULL

``	NULL
*	NULL
``	NULL
``	NULL
We	NULL
reasoned	NULL
that	NULL
the	NULL
simplest	NULL
means	NULL
of	NULL
inhibiting	NULL
HIF-1	NULL
effectors	NULL
responsible	NULL
for	NULL
tumor	NULL
growth	NULL
,	NULL
would	NULL
be	NULL
to	NULL
target	NULL
HIF-1	NULL
itself	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
HIF-l	NULL
«	NULL
is	NULL
a	NULL
suitable	NULL
target	NULL
to	NULL
attack	NULL
the	NULL
tumor	NULL
vasculature	NULL
.	NULL

To	NULL
date	NULL
,	NULL
the	NULL
long-held	NULL
promise	NULL
of	NULL
cancer	NULL
immunotherapy	NULL
has	NULL
not	NULL
been	NULL
realized	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
cancer	NULL
immunotherapy	NULL
can	NULL
be	NULL
made	NULL
more	NULL
effective	NULL
by	NULL
simultaneously	NULL
targeting	NULL
a	NULL
tumour	NULL
's	NULL
weapons	NULL
of	NULL
survival	NULL
,	NULL
defense	NULL
and	NULL
attack	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
an	NULL
attack	NULL
on	NULL
the	NULL
tumor	NULL
vasculature	NULL
combined	NULL
with	NULL
B7-1	NULL
immunotherapy	NULL
,	NULL
which	NULL
costimulates	NULL
antitumor	NULL
T	NULL
cells	NULL
and	NULL
generates	NULL
systemic	NULL
antitumor	NULL
immunity	NULL
,	NULL
overcomes	NULL
the	NULL
immune-resistance	NULL
of	NULL
large	NULL
tumors	NULL
.	NULL
``	NULL

Here	NULL
we	NULL
reveal	NULL
that	NULL
anti-HIF-la	NULL
therapy	NULL
greatly	NULL
enhances	NULL
the	NULL
therapeutic	NULL
efficacy	NULL
of	NULL
cancer	NULL
immunotherapy	NULL
involving	NULL
gene	NULL
transfer	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
costimulator	NULL
B7-1	NULL
into	NULL
tumors	NULL
in	NULL
sity	NULL
.	NULL
``	NULL

Results	NULL
Gene	NULL
transfer	NULL
of	NULL
an	NULL
expression	NULL
plasmid	NULL
encoding	NULL
antisense	NULL
HIF-1	NULL
«	NULL
induces	NULL
the	NULL
rejection	NULL
of	NULL
established	NULL
tumors	NULL
EL-4	NULL
tumors	NULL
of	NULL
0.1	NULL
cm	NULL
in	NULL
diameter	NULL
were	NULL
established	NULL
in	NULL
C57BL/6	NULL
mice	NULL
,	NULL
and	NULL
injected	NULL
with	NULL
a	NULL
DNA	NULL
/liposome	NULL
transfection	NULL
vehicle	NULL
containing	NULL
100	NULL
ug	NULL
of	NULL
antisense	NULL
HIF-l	NULL
«	NULL
peDNA3B	NULL
plasmid	NULL
DNA	NULL
.	NULL

Immunohistochemical	NULL
analysis	NULL
of	NULL
tumor	NULL
sections	NULL
prepared	NULL
2	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
,	NULL
revealed	NULL
antisense	NULL
therapy	NULL
resulted	NULL
in	NULL
almost	NULL
the	NULL
complete	NULL
inhibition	NULL
of	NULL
HIF-1a	NULL
«	NULL
expressed	NULL
endogenously	NULL
in	NULL
growing	NULL
tumors	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
compare	NULL
c	NULL
and	NULL
d	NULL
)	NULL
.	NULL

Down-regulation	NULL
of	NULL
HIF-l1	NULL
«	NULL
expression	NULL
was	NULL
confirmed	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
tumor	NULL
homogenates	NULL
(	NULL
Figure	NULL
1i	NULL
)	NULL
.	NULL

Tumor	NULL
growth	NULL
was	NULL
monitored	NULL
for	NULL
4	NULL
weeks	NULL
following	NULL
gene	NULL
transfer	NULL
(	NULL
Figure	NULL
?	NULL

a	NULL
)	NULL
.	NULL

A	NULL
comparison	NULL
was	NULL
made	NULL
with	NULL
mice	NULL
treated	NULL
with	NULL
100	NULL
ug	NULL
of	NULL
empty	NULL
vector	NULL
control	NULL
,	NULL
and	NULL
vector	NULL
encoding	NULL
the	NULL
T	NULL
cell	NULL
costimulator	NULL
B7-1	NULL
as	NULL
a	NULL
positive	NULL
con-trol	NULL
.	NULL
``	NULL

Tumors	NULL
grew	NULL
rapidly	NULL
in	NULL
the	NULL
control	NULL
group	NULL
,	NULL
reaching	NULL
1	NULL
cm	NULL
in	NULL
size	NULL
14-17	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
,	NULL
whereas	NULL
tumors	NULL
treated	NULL
with	NULL
the	NULL
antisense	NULL
HIF-1	NULL
«	NULL
plasmid	NULL
and	NULL
B7-1	NULL
completely	NULL
and	NULL
rapidly	NULL
regressed	NULL
within	NULL
1	NULL
week	NULL
of	NULL
gene	NULL
transfer	NULL
.	NULL

Mice	NULL
remained	NULL
tumor-free	NULL
for	NULL
a	NULL
further	NULL
21-day	NULL
period	NULL
during	NULL
which	NULL
they	NULL
were	NULL
moni-tored	NULL
.	NULL

There	NULL
was	NULL
no	NULL
significant	NULL
difference	NULL
between	NULL
the	NULL
growth	NULL
pattern	NULL
of	NULL
tumors	NULL
treated	NULL
with	NULL
B7-1	NULL
and	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
antisense	NULL
HIF-l	NULL
«	NULL
-treated	NULL
,	NULL
tumor-free	NULL
,	NULL
mice	NULL
were	NULL
rechallenged	NULL
with	NULL
1	NULL
x	NULL
10°	NULL
parental	NULL
EL-4	NULL
cells	NULL
,	NULL
palpable	NULL
tumors	NULL
appeared	NULL
15-20	NULL
days	NULL
later	NULL
in	NULL
all	NULL
the	NULL
mice	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
tumors	NULL
emerged	NULL
over	NULL
a	NULL
monitoring	NULL
period	NULL
of	NULL
2	NULL
months	NULL
in	NULL
mice	NULL
that	NULL
had	NULL
cleared	NULL
their	NULL
tumors	NULL
in	NULL
response	NULL
to	NULL
B7-1	NULL
immunotherapy	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
does	NULL
not	NULL
eradicate	NULL
large	NULL
tumors	NULL
,	NULL
but	NULL
slows	NULL
their	NULL
growth	NULL
We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
tumors	NULL
become	NULL
refractory	NULL
to	NULL
B7-1-mediated	NULL
immunotherapy	NULL
once	NULL
they	NULL
Antisense	NULL
HIF-1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
[	NULL
i	NULL
)	NULL
a	NULL
120	NULL
kDa	NULL
>	NULL
|	NULL
U	NULL
#	NULL
%	NULL
*	NULL
HIF-l1a	NULL
VEGF	NULL
Figure	NULL
1	NULL
Immunohistochemistry	NULL
of	NULL
tumor	NULL
sections	NULL
following	NULL
gene	NULL
transfer	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
costimulator	NULL
B7-1	NULL
,	NULL
and	NULL
an	NULL
anti-angiogenic	NULL
plasmid	NULL
encoding	NULL
antisense	NULL
HIF-1	NULL
@	NULL
«	NULL
.	NULL

(	NULL
a	NULL
,	NULL
b	NULL
)	NULL
Gene	NULL
transfer	NULL
leads	NULL
to	NULL
overexpression	NULL
of	NULL
B7-1	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
90	NULL
%	NULL
of	NULL
tumor	NULL
cells	NULL
.	NULL

Tumors	NULL
0.1	NULL
cm	NULL
in	NULL
diameter	NULL
were	NULL
injected	NULL
with	NULL
DOTAP	NULL
liposomes	NULL
containing	NULL
either	NULL
empty	NULL
vector	NULL
(	NULL
a	NULL
)	NULL
,	NULL
or	NULL
B7-1	NULL
expression	NULL
vector	NULL
(	NULL
b	NULL
)	NULL
.	NULL

Illustrated	NULL
are	NULL
representative	NULL
tumor	NULL
sections	NULL
prepared	NULL
2	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
,	NULL
and	NULL
stained	NULL
brown	NULL
with	NULL
the	NULL
anti-B7-1	NULL
mAb	NULL
1G10	NULL
(	NULL
x100	NULL
magnification	NULL
)	NULL
.	NULL

(	NULL
c-f	NULL
)	NULL
Down-regulation	NULL
of	NULL
HIF-1a	NULL
and	NULL
VEGF	NULL
by	NULL
antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
.	NULL

Tumors	NULL
0.1	NULL
cm	NULL
in	NULL
diameter	NULL
were	NULL
injected	NULL
with	NULL
DOTAP	NULL
liposomes	NULL
containing	NULL
either	NULL
empty	NULL
vector	NULL
(	NULL
c	NULL
,	NULL
e	NULL
)	NULL
,	NULL
or	NULL
antisense	NULL
HIF-1a	NULL
cDNA	NULL
(	NULL
d	NULL
,	NULL
f	NULL
)	NULL
.	NULL

Illustrated	NULL
are	NULL
representative	NULL
tumor	NULL
sections	NULL
prepared	NULL
4	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
,	NULL
and	NULL
stained	NULL
brown	NULL
with	NULL
mAbs	NULL
against	NULL
HIF-1a	NULL
«	NULL
(	NULL
c	NULL
,	NULL
d	NULL
)	NULL
,	NULL
and	NULL
VEGF	NULL
(	NULL
e	NULL
,	NULL
f	NULL
)	NULL
(	NULL
x100	NULL
magnification	NULL
)	NULL
.	NULL

(	NULL
g	NULL
,	NULL
h	NULL
)	NULL
Antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
blocks	NULL
the	NULL
formation	NULL
of	NULL
new	NULL
tumor	NULL
blood	NULL
vessels	NULL
.	NULL

Illustrated	NULL
are	NULL
sections	NULL
prepared	NULL
from	NULL
0.4	NULL
cm	NULL
tumors	NULL
injected	NULL
4	NULL
days	NULL
earlier	NULL
with	NULL
either	NULL
empty	NULL
vector	NULL
(	NULL
pcDNA3	NULL
)	NULL
(	NULL
g	NULL
)	NULL
,	NULL
or	NULL
antisense	NULL
HIF-1	NULL
«	NULL
(	NULL
h	NULL
)	NULL
.	NULL

Endothelial	NULL
cells	NULL
within	NULL
sections	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
anti-CD31	NULL
mAb	NULL
,	NULL
revealing	NULL
tumor	NULL
blood	NULL
vessels	NULL
(	NULL
x10	NULL
magnification	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
expression	NULL
of	NULL
HIF-1	NULL
«	NULL
(	NULL
i	NULL
)	NULL
and	NULL
VEGF	NULL
(	NULL
j	NULL
)	NULL
in	NULL
tumor	NULL
homogenates	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

Homogenates	NULL
were	NULL
prepared	NULL
from	NULL
tumors	NULL
treated	NULL
with	NULL
empty	NULL
plasmid	NULL
(	NULL
lanes	NULL
1	NULL
)	NULL
,	NULL
and	NULL
plasmids	NULL
encoding	NULL
sense	NULL
HIF-1	NULL
«	NULL
(	NULL
lanes	NULL
2	NULL
)	NULL
,	NULL
and	NULL
anti-sense	NULL
HIF-1	NULL
«	NULL
(	NULL
lanes	NULL
3	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
screened	NULL
with	NULL
anti-HIF-1	NULL
«	NULL
or	NULL
anti-VEGF	NULL
mAbs	NULL
,	NULL
as	NULL
indicated	NULL
.	NULL

Gene	NULL
Therapy	NULL
Antisense	NULL
HIF-L1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
640	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
a	NULL
1.2	NULL
[	NULL
e	NULL
aHIF-1	NULL
'	NULL
]	NULL
|®Be74	NULL
|	NULL
p.4	NULL
|	NULL
|aEmpty	NULL
Vector	NULL
]	NULL
0.6	NULL
Tumour	NULL
size	NULL
(	NULL
cm	NULL
,	NULL
diameter	NULL
)	NULL
Lx	NULL
L.	NULL
Day0	NULL
Day3	NULL
Day6	NULL
Day9	NULL
_	NULL
Day12	NULL
Day15	NULL
-	NULL
Day18	NULL
Days	NULL
after	NULL
gene	NULL
injection	NULL
iia	NULL
’	NULL
l—llF-ﬁ	NULL
|	NULL
‘	NULL
L	NULL
DEmpty	NULL
Vector	NULL
0.8	NULL
0.6	NULL
0.4	NULL
0.2	NULL
Tumour	NULL
size	NULL
(	NULL
cm	NULL
,	NULL
diameter	NULL
)	NULL
Day0	NULL
Day3	NULL
Day6	NULL
Day	NULL
$	NULL
Day12	NULL
Day15	NULL
Days	NULL
after	NULL
gene	NULL
injection	NULL
Figure	NULL
2	NULL
Monotherapies	NULL
utilizing	NULL
antisense	NULL
HIF-1	NULL
«	NULL
anti-angiogenic	NULL
therapy	NULL
,	NULL
and	NULL
B7-1-mediated	NULL
immunotherapy	NULL
,	NULL
are	NULL
only	NULL
effective	NULL
against	NULL
small	NULL
tumors	NULL
.	NULL

Established	NULL
tumors	NULL
approximately	NULL
0.1	NULL
(	NULL
a	NULL
)	NULL
and	NULL
0.4	NULL
(	NULL
b	NULL
)	NULL
cm	NULL
in	NULL
diameter	NULL
,	NULL
were	NULL
injected	NULL
at	NULL
day	NULL
0	NULL
with	NULL
DOTAP	NULL
liposomes	NULL
containing	NULL
either	NULL
B7-1	NULL
cDNA	NULL
,	NULL
antisense	NULL
HIF-1	NULL
«	NULL
cDNA	NULL
;	NULL
or	NULL
empty	NULL
vector	NULL
in	NULL
the	NULL
case	NULL
of	NULL
control	NULL
animals	NULL
.	NULL

The	NULL
sizes	NULL
(	NULL
cm	NULL
)	NULL
of	NULL
tumors	NULL
were	NULL
recorded	NULL
following	NULL
gene	NULL
transfer	NULL
.	NULL

Complete	NULL
tumor	NULL
regression	NULL
is	NULL
denoted	NULL
by	NULL
vertical	NULL
arrows	NULL
.	NULL

Mice	NULL
were	NULL
killed	NULL
if	NULL
tumors	NULL
reached	NULL
more	NULL
than	NULL
1	NULL
cm	NULL
in	NULL
diameter	NULL
(	NULL
denoted	NULL
by	NULL
stars	NULL
)	NULL
.	NULL

Cured	NULL
mice	NULL
were	NULL
rechallenged	NULL
with	NULL
1x	NULL
10°	NULL
parental	NULL
tumor	NULL
cells	NULL
.	NULL

No	NULL
tumors	NULL
developed	NULL
in	NULL
mice	NULL
cured	NULL
by	NULL
B7-1	NULL
therapy	NULL
,	NULL
whereas	NULL
all	NULL
mice	NULL
treated	NULL
by	NULL
antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
developed	NULL
tumors	NULL
during	NULL
the	NULL
2	NULL
months	NULL
they	NULL
were	NULL
monitored	NULL
(	NULL
refer	NULL
to	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Table	NULL
1	NULL
Rechallenge	NULL
of	NULL
cured	NULL
mice	NULL
with	NULL
parental	NULL
tumour	NULL
cells	NULL
reach	NULL
0.3	NULL
cm	NULL
in	NULL
diameter	NULL
.	NULL
``	NULL

This	NULL
is	NULL
shown	NULL
in	NULL
Figure	NULL
2b	NULL
where	NULL
large	NULL
tumors	NULL
(	NULL
0.4	NULL
cm	NULL
diameter	NULL
)	NULL
were	NULL
refractory	NULL
to	NULL
B7-1	NULL
immunotherapy	NULL
.	NULL

The	NULL
failure	NULL
of	NULL
B7-1	NULL
therapy	NULL
to	NULL
combat	NULL
large	NULL
tumors	NULL
is	NULL
not	NULL
the	NULL
result	NULL
of	NULL
poor	NULL
transfection	NULL
efficiency	NULL
as	NULL
B7-1	NULL
gene	NULL
transfer	NULL
led	NULL
to	NULL
expression	NULL
of	NULL
B7-1	NULL
in	NULL
90	NULL
%	NULL
of	NULL
tumor	NULL
cells	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
compare	NULL
a	NULL
and	NULL
b	NULL
)	NULL
,	NULL
as	NULL
reported	NULL
previously	NULL
.	NULL
``	NULL

To	NULL
determine	NULL
whether	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
therapy	NULL
was	NULL
similarly	NULL
ineffective	NULL
against	NULL
large	NULL
tumors	NULL
,	NULL
EL-4	NULL
tumors	NULL
of	NULL
0.4	NULL
cm	NULL
in	NULL
diameter	NULL
were	NULL
estab-lished	NULL
,	NULL
and	NULL
treated	NULL
with	NULL
100	NULL
pg	NULL
antisense	NULL
HIF-l	NULL
«	NULL
expression	NULL
plasmid	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
2b	NULL
,	NULL
none	NULL
of	NULL
the	NULL
mice	NULL
rejected	NULL
their	NULL
tumors	NULL
,	NULL
albeit	NULL
there	NULL
was	NULL
a	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
inhibition	NULL
of	NULL
tumor	NULL
growth	NULL
,	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
B7-1	NULL
therapy	NULL
.	NULL

All	NULL
tumors	NULL
eventually	NULL
reached	NULL
1	NULL
cm	NULL
in	NULL
diameter	NULL
within	NULL
2	NULL
weeks	NULL
,	NULL
and	NULL
mice	NULL
had	NULL
to	NULL
be	NULL
killed	NULL
.	NULL

Vascular	NULL
attack	NULL
by	NULL
antisense	NULL
HIF-1	NULL
«	NULL
synergizes	NULL
with	NULL
B7-1	NULL
immunotherapy	NULL
to	NULL
eradicate	NULL
large	NULL
tumors	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
``	NULL
that	NULL
an	NULL
attack	NULL
on	NULL
tumor	NULL
blood	NULL
vessels	NULL
by	NULL
the	NULL
flavone	NULL
acetic	NULL
acid-related	NULL
agent	NULL
5,6-dimethylxanthenone-4-acetic	NULL
acid	NULL
(	NULL
DMXAA	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
B7.1-mediated	NULL
immunotherapy	NULL
overcomes	NULL
immune-resistance	NULL
and	NULL
leads	NULL
to	NULL
the	NULL
eradication	NULL
of	NULL
large	NULL
tumors	NULL
.	NULL

Here	NULL
we	NULL
consider	NULL
the	NULL
possibility	NULL
that	NULL
an	NULL
anti-HIF-la	NULL
reagent	NULL
might	NULL
be	NULL
a	NULL
suitable	NULL
anti-angiogenic	NULL
substitute	NULL
for	NULL
DMXAA	NULL
in	NULL
combination	NULL
therapy	NULL
,	NULL
given	NULL
the	NULL
toxicity	NULL
of	NULL
DMXAA	NULL
at	NULL
high	NULL
therapeutic	NULL
doses	NULL
.	NULL
``	NULL

''	NULL
``	NULL
For	NULL
combination	NULL
therapy	NULL
,	NULL
0.4	NULL
cm	NULL
diameter	NULL
tumors	NULL
were	NULL
first	NULL
injected	NULL
with	NULL
DNA	NULL
complexes	NULL
containing	NULL
100	NULL
ug	NULL
B7-1	NULL
,	NULL
followed	NULL
48	NULL
h	NULL
later	NULL
by	NULL
100	NULL
pg	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
plasmids	NULL
.	NULL

Timed	NULL
delivery	NULL
of	NULL
anti-angiogenic	NULL
and	NULL
immunothera-peutic	NULL
agents	NULL
has	NULL
previously	NULL
proven	NULL
to	NULL
be	NULL
critical	NULL
to	NULL
the	NULL
success	NULL
of	NULL
combinational	NULL
therapy	NULL
.	NULL
``	NULL

''	NULL
Combined	NULL
gene	NULL
therapy	NULL
led	NULL
to	NULL
complete	NULL
tumor	NULL
regression	NULL
within	NULL
10	NULL
days	NULL
,	NULL
and	NULL
mice	NULL
remained	NULL
tumor-free	NULL
for	NULL
3	NULL
weeks	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
systemic	NULL
antitumor	NULL
immunity	NULL
had	NULL
been	NULL
generated	NULL
,	NULL
cured	NULL
mice	NULL
were	NULL
rechallenged	NULL
with	NULL
1	NULL
x	NULL
10°	NULL
parental	NULL
tumor	NULL
cells	NULL
.	NULL

Such	NULL
mice	NULL
resisted	NULL
the	NULL
chal-lenge	NULL
,	NULL
and	NULL
remained	NULL
tumor-free	NULL
for	NULL
at	NULL
least	NULL
2	NULL
months	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
,	NULL
indicating	NULL
an	NULL
antitumor	NULL
immune	NULL
memory	NULL
response	NULL
had	NULL
been	NULL
generated	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
B7-1	NULL
immunotherapy	NULL
was	NULL
combined	NULL
with	NULL
an	NULL
expression	NULL
plasmid	NULL
encoding	NULL
the	NULL
HIF-l1	NULL
«	NULL
cDNA	NULL
fragment	NULL
inserted	NULL
into	NULL
pecDNA3	NULL
in	NULL
a	NULL
sense	NULL
orientation	NULL
.	NULL

In	NULL
marked	NULL
contrast	NULL
to	NULL
the	NULL
above	NULL
results	NULL
,	NULL
sense	NULL
HIF-1	NULL
«	NULL
could	NULL
not	NULL
enhance	NULL
the	NULL
therapeutic	NULL
efficacy	NULL
of	NULL
B7-1	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
,	NULL
producing	NULL
results	NULL
that	NULL
were	NULL
not	NULL
statistically	NULL
(	NULL
P	NULL
>	NULL
0.05	NULL
)	NULL
different	NULL
from	NULL
mice	NULL
treated	NULL
with	NULL
B7-1	NULL
alone	NULL
.	NULL

Genes	NULL
Tumors	NULL
size	NULL
(	NULL
cm	NULL
,	NULL
diameter	NULL
)	NULL
Detectable	NULL
tumors	NULL
Day	NULL
10	NULL
Day	NULL
15	NULL
Day	NULL
20	NULL
Day	NULL
25	NULL
Day	NULL
30	NULL
Day	NULL
40	NULL
Day	NULL
60	NULL
B7-1	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
0/6	NULL
B7-1+aHIF	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
-	NULL
0/6	NULL
aHIF	NULL
-	NULL
0.08	NULL
£	NULL
0.09	NULL
0.36	NULL
£0.15	NULL
0.78	NULL
£	NULL
0.17	NULL
0.98	NULL
£	NULL
0.05	NULL
killed	NULL
6/6	NULL
Mice	NULL
cured	NULL
of	NULL
their	NULL
tumors	NULL
following	NULL
gene	NULL
transfer	NULL
of	NULL
B7-1	NULL
(	NULL
0.1	NULL
em	NULL
tumors	NULL
)	NULL
,	NULL
aHIF	NULL
(	NULL
0.1	NULL
em	NULL
tumors	NULL
)	NULL
,	NULL
or	NULL
B7-1+aHIF	NULL
(	NULL
0.4	NULL
cm	NULL
tumors	NULL
)	NULL
(	NULL
as	NULL
indicated	NULL
in	NULL
Figures	NULL
2	NULL
and	NULL
3	NULL
)	NULL
were	NULL
rechallenged	NULL
s.c.	NULL
with	NULL
1	NULL
x	NULL
10°	NULL
EL-4	NULL
cells	NULL
.	NULL

All	NULL
the	NULL
mice	NULL
were	NULL
monitored	NULL
for	NULL
2	NULL
months	NULL
and	NULL
tumor	NULL
occurrence	NULL
and	NULL
sizes	NULL
were	NULL
measured	NULL
every	NULL
5	NULL
days	NULL
.	NULL

Gene	NULL
Therapy	NULL
1.2	NULL
&	NULL
B7-1	NULL
+	NULL
aHIF	NULL
q	NULL
|	NULL
aB7-4	NULL
+	NULL
sHIF	NULL
m	NULL
B7-1	NULL
&	NULL
co	NULL
C	NULL
Empty	NULL
vector	NULL
&	NULL
&	NULL
i	NULL
o	NULL
p.	NULL
&	NULL
No	NULL
1	NULL
Day0	NULL
-	NULL
Day3	NULL
-	NULL
Day6	NULL
oO	NULL
Tumour	NULL
size	NULL
(	NULL
cm	NULL
,	NULL
diameter	NULL
)	NULL
Day9	NULL
Day12	NULL
Day15	NULL
Days	NULL
after	NULL
gene	NULL
injection	NULL
Figure	NULL
3	NULL
Combining	NULL
antisense	NULL
HIF-1a	NULL
«	NULL
therapy	NULL
with	NULL
B7.1	NULL
immunotherapy	NULL
causes	NULL
the	NULL
rapid	NULL
rejection	NULL
of	NULL
large	NULL
tumors	NULL
.	NULL

Tumors	NULL
0.4	NULL
cm	NULL
in	NULL
diameter	NULL
were	NULL
injected	NULL
with	NULL
DOTAP	NULL
liposomes	NULL
containing	NULL
B7-1	NULL
cDNA	NULL
,	NULL
followed	NULL
48	NULL
h	NULL
later	NULL
by	NULL
either	NULL
antisense	NULL
(	NULL
aHIF	NULL
)	NULL
or	NULL
sense	NULL
(	NULL
sHIF	NULL
)	NULL
HIF-l	NULL
«	NULL
cDNA	NULL
.	NULL

Control	NULL
animals	NULL
received	NULL
empty	NULL
vector	NULL
,	NULL
or	NULL
B7-1	NULL
vector	NULL
alone	NULL
.	NULL

The	NULL
sizes	NULL
(	NULL
cm	NULL
)	NULL
of	NULL
tumors	NULL
were	NULL
recorded	NULL
following	NULL
gene	NULL
transfer	NULL
.	NULL

Mice	NULL
were	NULL
killed	NULL
if	NULL
tumors	NULL
reached	NULL
more	NULL
than	NULL
1	NULL
cm	NULL
in	NULL
diameter	NULL
(	NULL
denoted	NULL
by	NULL
stars	NULL
)	NULL
.	NULL

Complete	NULL
tumor	NULL
regression	NULL
is	NULL
denoted	NULL
by	NULL
vertical	NULL
arrows	NULL
.	NULL

Cured	NULL
mice	NULL
were	NULL
rechallenged	NULL
with	NULL
1	NULL
x	NULL
10°	NULL
parental	NULL
tumor	NULL
cells	NULL
,	NULL
but	NULL
developed	NULL
no	NULL
tumors	NULL
during	NULL
the	NULL
2	NULL
months	NULL
they	NULL
were	NULL
monitored	NULL
(	NULL
refer	NULL
to	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Composition	NULL
of	NULL
the	NULL
effector	NULL
cell	NULL
population	NULL
We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
NK	NULL
cells	NULL
and	NULL
CD8+*	NULL
T	NULL
cells	NULL
are	NULL
largely	NULL
responsible	NULL
for	NULL
B7-1-mediated	NULL
antitumor	NULL
immunity	NULL
.	NULL
``	NULL

NK	NULL
cells	NULL
,	NULL
and	NULL
CD8*	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
are	NULL
responsible	NULL
for	NULL
antitumor	NULL
immunity	NULL
generated	NULL
by	NULL
combination	NULL
therapy	NULL
with	NULL
antisense	NULL
HIF-1	NULL
«	NULL
and	NULL
B7-1	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NK	NULL
cells	NULL
are	NULL
solely	NULL
responsible	NULL
for	NULL
the	NULL
antitumor	NULL
effects	NULL
of	NULL
anti-sense	NULL
HIF-1	NULL
«	NULL
monotherapy	NULL
,	NULL
and	NULL
T	NULL
cells	NULL
appear	NULL
not	NULL
to	NULL
be	NULL
involved	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
inhibits	NULL
VEGF	NULL
expression	NULL
,	NULL
and	NULL
reduces	NULL
the	NULL
density	NULL
of	NULL
tumor	NULL
blood	NULL
vessels	NULL
Given	NULL
that	NULL
antisense	NULL
HIF-l	NULL
«	NULL
down-regulated	NULL
the	NULL
expression	NULL
of	NULL
HIF-1	NULL
«	NULL
in	NULL
EL-4	NULL
tumor	NULL
cells	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
expression	NULL
of	NULL
downstream	NULL
effectors	NULL
such	NULL
as	NULL
VEGF	NULL
was	NULL
abolished	NULL
.	NULL

Expression	NULL
of	NULL
VEGF	NULL
was	NULL
specifically	NULL
reduced	NULL
in	NULL
response	NULL
to	NULL
antisense	NULL
HIF-1	NULL
«	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
immunohistochemical	NULL
staining	NULL
of	NULL
tumor	NULL
sections	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
compare	NULL
e	NULL
and	NULL
£	NULL
)	NULL
,	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
tumor	NULL
homogenates	NULL
(	NULL
Figure	NULL
1j	NULL
)	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
statistically	NULL
significant	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
30	NULL
%	NULL
reduction	NULL
in	NULL
tumor	NULL
vessel	NULL
density	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
compare	NULL
g	NULL
and	NULL
h	NULL
;	NULL
Figure	NULL
5a	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
mock	NULL
treatment	NULL
with	NULL
empty	NULL
vector	NULL
.	NULL

The	NULL
median	NULL
and	NULL
90th	NULL
centile	NULL
distances	NULL
to	NULL
the	NULL
nearest	NULL
anti-CD31	NULL
mAb-labelled	NULL
venules	NULL
from	NULL
an	NULL
array	NULL
of	NULL
points	NULL
within	NULL
tumors	NULL
treated	NULL
with	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
were	NULL
significantly	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
longer	NULL
than	NULL
those	NULL
in	NULL
tumors	NULL
treated	NULL
with	NULL
empty	NULL
vector	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Tumor	NULL
blood	NULL
vessels	NULL
present	NULL
after	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
therapy	NULL
were	NULL
small	NULL
and	NULL
poorly	NULL
formed	NULL
(	NULL
Figure	NULL
1	NULL
,	NULL
compare	NULL
g	NULL
and	NULL
h	NULL
)	NULL
.	NULL

Discussion	NULL
Strategies	NULL
that	NULL
target	NULL
HIF-1	NULL
have	NULL
therapeutic	NULL
potential	NULL
in	NULL
treating	NULL
cancer	NULL
The	NULL
impetus	NULL
for	NULL
the	NULL
present	NULL
study	NULL
stemmed	NULL
from	NULL
a	NULL
previous	NULL
report	NULL
in	NULL
which	NULL
we	NULL
demonstrated	NULL
that	NULL
immune	NULL
Antisense	NULL
HIF-1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
a	NULL
1.4	NULL
641	NULL
=	NULL
,	NULL
ion	NULL
|	NULL
WO	NULL
D	NULL
CD4+	NULL
T	NULL
cell	NULL
deplet	NULL
912	NULL
+	NULL
T	NULL
cell	NULL
depletion	NULL
S7	NULL
D	NULL
H	NULL
1	NULL
{	NULL
B14	NULL
D	NULL
N	NULL
|	NULL
021	NULL
D	NULL
o	NULL
0.8	NULL
m	NULL
0.6	NULL
;	NULL
©	NULL
.	NULL

=	NULL
0.4	NULL
I20.2-	NULL
0	NULL
.	NULL

3	NULL
1.2	NULL
|CD8+	NULL
T	NULL
cell	NULL
depletion	NULL
Figure	NULL
4	NULL
Immune	NULL
cell	NULL
subsets	NULL
responsible	NULL
for	NULL
antitumor	NULL
immunity	NULL
.	NULL

Mice	NULL
were	NULL
treated	NULL
with	NULL
anti-CD4	NULL
(	NULL
GK1.5	NULL
)	NULL
,	NULL
anti-CD8	NULL
(	NULL
53-6.72	NULL
)	NULL
,	NULL
and	NULL
anti-NK	NULL
cell	NULL
(	NULL
PK136	NULL
)	NULL
mAbs	NULL
4	NULL
days	NULL
before	NULL
gene	NULL
transfer	NULL
,	NULL
and	NULL
every	NULL
alternate	NULL
day	NULL
for	NULL
the	NULL
duration	NULL
of	NULL
the	NULL
experiment	NULL
.	NULL

The	NULL
size	NULL
(	NULL
cm	NULL
)	NULL
of	NULL
tumors	NULL
was	NULL
monitored	NULL
for	NULL
21	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
.	NULL

Anti-CD8	NULL
and	NULL
anti-NK	NULL
mAbs	NULL
almost	NULL
completely	NULL
abrogated	NULL
tumor	NULL
rejection	NULL
in	NULL
response	NULL
to	NULL
B7-1	NULL
,	NULL
and	NULL
combination	NULL
B7-1/antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
,	NULL
whereas	NULL
the	NULL
efficacy	NULL
of	NULL
anti-sense	NULL
HIF-1	NULL
«	NULL
monotherapy	NULL
was	NULL
dependent	NULL
on	NULL
NK	NULL
cells	NULL
.	NULL

resistance	NULL
of	NULL
tumors	NULL
can	NULL
be	NULL
overcome	NULL
by	NULL
combining	NULL
B7-1	NULL
immunotherapy	NULL
with	NULL
a	NULL
concerted	NULL
attack	NULL
on	NULL
the	NULL
tumor	NULL
vasculature	NULL
delivered	NULL
by	NULL
the	NULL
drug	NULL
5,6-dimethylxan-thenone-4-acetic	NULL
acid	NULL
(	NULL
DMXAA	NULL
)	NULL
.	NULL

``	NULL
°	NULL
In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
anti-HIF-la	NULL
«	NULL
reagents	NULL
would	NULL
be	NULL
suitable	NULL
substitutes	NULL
for	NULL
DMXAA	NULL
in	NULL
combination	NULL
with	NULL
B7-l-mediated	NULL
immunotherapy	NULL
,	NULL
given	NULL
the	NULL
high	NULL
toxicity	NULL
of	NULL
DMXAA	NULL
.	NULL

Here	NULL
we	NULL
have	NULL
demonstrated	NULL
for	NULL
the	NULL
first	NULL
time	NULL
that	NULL
gene	NULL
transfer	NULL
of	NULL
antisense	NULL
HIF-l	NULL
«	NULL
vectors	NULL
into	NULL
established	NULL
tumors	NULL
is	NULL
able	NULL
to	NULL
cause	NULL
the	NULL
complete	NULL
regression	NULL
of	NULL
small	NULL
tumors	NULL
.	NULL

While	NULL
tumors	NULL
did	NULL
not	NULL
reappear	NULL
for	NULL
3	NULL
weeks	NULL
after	NULL
complete	NULL
regression	NULL
,	NULL
we	NULL
can	NULL
not	NULL
discount	NULL
the	NULL
possibility	NULL
that	NULL
they	NULL
had	NULL
regressed	NULL
to	NULL
microscopic	NULL
dormant	NULL
nodules	NULL
,	NULL
rather	NULL
than	NULL
being	NULL
completely	NULL
eradicated	NULL
,	NULL
as	NULL
occurs	NULL
with	NULL
repeated	NULL
anti-angiogenic	NULL
therapy	NULL
employing	NULL
angiostatin®*	NULL
and	NULL
endostatin	NULL
.	NULL
``	NULL

'	NULL
The	NULL
complete	NULL
and	NULL
permanent	NULL
regression	NULL
of	NULL
tumors	NULL
in	NULL
response	NULL
to	NULL
a	NULL
single	NULL
injection	NULL
of	NULL
Gene	NULL
Therapy	NULL
Antisense	NULL
HIF-L1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
642	NULL
§	NULL
m	NULL
Vessel	NULL
counts	NULL
per	NULL
surface	NULL
area	NULL
pCDNA3	NULL
aHIF	NULL
n=	NULL
6	NULL
n=	NULL
5	NULL
o	NULL
60	NULL
-+	NULL
50	NULL
-+	NULL
30	NULL
»	NULL
o	NULL
|	NULL
,	NULL
I	NULL
10	NULL
Distance	NULL
to	NULL
nearest	NULL
blood	NULL
vessel	NULL
(	NULL
um	NULL
}	NULL
peDNA¥3	NULL
aHIF	NULL
median	NULL
median	NULL
peDNA¥3	NULL
aHIF	NULL
90th	NULL
centile	NULL
90th	NULL
centile	NULL
n=	NULL
6	NULL
n=	NULL
5	NULL
n=	NULL
6	NULL
n=	NULL
5	NULL
Figure	NULL
5	NULL
Measurement	NULL
of	NULL
tumor	NULL
vascularity	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Tumor	NULL
blood	NULL
vessels	NULL
stained	NULL
with	NULL
the	NULL
anti-CD31	NULL
mAb	NULL
were	NULL
counted	NULL
in	NULL
blindly	NULL
chosen	NULL
random	NULL
fields	NULL
to	NULL
record	NULL
mean	NULL
vessel	NULL
density	NULL
per	NULL
surface	NULL
area	NULL
(	NULL
0.155	NULL
mm	NULL
)	NULL
.	NULL

n	NULL
,	NULL
number	NULL
of	NULL
tumors	NULL
assessed	NULL
.	NULL

A	NULL
significant	NULL
difference	NULL
in	NULL
mean	NULL
vessel	NULL
counts	NULL
between	NULL
tumors	NULL
treated	NULL
with	NULL
antisense	NULL
HIF-l	NULL
«	NULL
versus	NULL
peDNA3	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
is	NULL
donated	NULL
by	NULL
stars	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Histograms	NULL
showing	NULL
the	NULL
median	NULL
and	NULL
90th	NULL
centile	NULL
distance	NULL
to	NULL
the	NULL
nearest	NULL
anti-CD31	NULL
mAb-stained	NULL
vessel	NULL
from	NULL
an	NULL
array	NULL
point	NULL
within	NULL
each	NULL
tumor	NULL
.	NULL

The	NULL
mean	NULL
values	NULL
for	NULL
tumors	NULL
treated	NULL
with	NULL
pcDNA3	NULL
and	NULL
anti-sense	NULL
HIF-la	NULL
«	NULL
are	NULL
given	NULL
(	NULL
+s.d	NULL
.	NULL
)	NULL

.	NULL

n	NULL
,	NULL
number	NULL
of	NULL
tumors	NULL
assessed	NULL
.	NULL

A	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
median	NULL
or	NULL
90th	NULL
centile	NULL
distance	NULL
to	NULL
the	NULL
nearest	NULL
blood	NULL
vessels	NULL
of	NULL
tumors	NULL
treated	NULL
with	NULL
antisense	NULL
HIF-1a	NULL
versus	NULL
pcDNA3	NULL
(	NULL
both	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
is	NULL
donated	NULL
by	NULL
stars	NULL
.	NULL

antisense	NULL
HIF-1	NULL
«	NULL
is	NULL
unusual	NULL
for	NULL
an	NULL
anti-angiogenic	NULL
agent	NULL
,	NULL
given	NULL
that	NULL
such	NULL
agents	NULL
normally	NULL
cause	NULL
only	NULL
transient	NULL
tumor	NULL
regression	NULL
.	NULL

By	NULL
some	NULL
unknown	NULL
mechanism	NULL
,	NULL
anti-HIF-l	NULL
«	NULL
therapy	NULL
appears	NULL
to	NULL
render	NULL
tumors	NULL
susceptible	NULL
to	NULL
an	NULL
attack	NULL
by	NULL
NK	NULL
cells	NULL
,	NULL
yet	NULL
it	NULL
does	NULL
not	NULL
stimulate	NULL
T	NULL
cell-mediated	NULL
antitumor	NULL
immunity	NULL
,	NULL
as	NULL
does	NULL
B7-1	NULL
.	NULL

Since	NULL
different	NULL
angiogenic	NULL
factors	NULL
either	NULL
promote	NULL
or	NULL
inhibit	NULL
NK	NULL
cell	NULL
adhesion	NULL
to	NULL
endothelium	NULL
,	NULL
``	NULL
*	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
antisense	NULL
HIF-l	NULL
«	NULL
therapy	NULL
shifts	NULL
the	NULL
balance	NULL
in	NULL
favor	NULL
of	NULL
NK	NULL
cell	NULL
adhesion	NULL
to	NULL
tumor	NULL
microvessels	NULL
,	NULL
and	NULL
thereby	NULL
facilitates	NULL
the	NULL
access	NULL
of	NULL
NK	NULL
cells	NULL
to	NULL
the	NULL
tumor	NULL
.	NULL

Thus	NULL
the	NULL
efficacy	NULL
of	NULL
antisense	NULL
HIF-1	NULL
«	NULL
therapy	NULL
may	NULL
arise	NULL
both	NULL
from	NULL
an	NULL
attack	NULL
Gene	NULL
Therapy	NULL
on	NULL
the	NULL
tumor	NULL
vasculature	NULL
,	NULL
and	NULL
enhancement	NULL
of	NULL
NK	NULL
cell-mediated	NULL
immunity	NULL
.	NULL

Anti-sense	NULL
HIF-l	NULL
«	NULL
therapy	NULL
could	NULL
not	NULL
cause	NULL
regression	NULL
of	NULL
large	NULL
(	NULL
0.4	NULL
em	NULL
diameter	NULL
)	NULL
tumors	NULL
,	NULL
but	NULL
it	NULL
did	NULL
delay	NULL
tumor	NULL
growth	NULL
.	NULL

Similarly	NULL
,	NULL
we	NULL
have	NULL
consistently	NULL
found	NULL
that	NULL
gene	NULL
transfer	NULL
of	NULL
T	NULL
cell	NULL
costimulatory	NULL
integrin	NULL
ligands	NULL
,	NULL
and	NULL
B7	NULL
molecules	NULL
,	NULL
into	NULL
tumors	NULL
less	NULL
than	NULL
0.3	NULL
cm	NULL
in	NULL
diameter	NULL
causes	NULL
rapid	NULL
tumor	NULL
rejection	NULL
,	NULL
whereas	NULL
tumors	NULL
become	NULL
increasingly	NULL
refractory	NULL
to	NULL
treatment	NULL
as	NULL
their	NULL
size	NULL
increases	NULL
.	NULL
``	NULL

''	NULL
Larger	NULL
tumors	NULL
appear	NULL
to	NULL
actively	NULL
suppress	NULL
or	NULL
avoid	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Our	NULL
results	NULL
confirm	NULL
that	NULL
immunotherapy	NULL
employing	NULL
B7-1	NULL
and	NULL
other	NULL
CAMs	NULL
has	NULL
limited	NULL
therapeutic	NULL
use	NULL
,	NULL
unless	NULL
their	NULL
therapeutic	NULL
efficacy	NULL
is	NULL
improved	NULL
by	NULL
combination	NULL
with	NULL
other	NULL
therapeutic	NULL
modalities	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
enhances	NULL
B7-1-mediated	NULL
immunotherapy	NULL
The	NULL
data	NULL
demonstrate	NULL
that	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
and	NULL
B7-1-immunotherapies	NULL
synergize	NULL
in	NULL
causing	NULL
the	NULL
rapid	NULL
rejection	NULL
of	NULL
large	NULL
EL-4	NULL
tumors	NULL
,	NULL
and	NULL
generation	NULL
of	NULL
potent	NULL
antitumor	NULL
systemic	NULL
immunity	NULL
;	NULL
thereby	NULL
establishing	NULL
that	NULL
anti-HIF	NULL
reagents	NULL
can	NULL
substitute	NULL
for	NULL
DMXAA	NULL
as	NULL
an	NULL
antivascular	NULL
agent	NULL
.	NULL

Cured	NULL
mice	NULL
rechallenged	NULL
with	NULL
live	NULL
EL-4	NULL
cells	NULL
remained	NULL
tumor-free	NULL
for	NULL
at	NULL
least	NULL
3	NULL
months	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
,	NULL
``	NULL
timed	NULL
delivery	NULL
of	NULL
the	NULL
reagents	NULL
,	NULL
where	NULL
B7-1	NULL
vectors	NULL
are	NULL
administered	NULL
first	NULL
,	NULL
followed	NULL
by	NULL
antisense	NULL
HIF-1a	NULL
vectors	NULL
proved	NULL
to	NULL
be	NULL
effective	NULL
.	NULL

Antisense	NULL
HIF-l	NULL
«	NULL
may	NULL
facilitate	NULL
B7-1	NULL
immunotherapy	NULL
by	NULL
inhibiting	NULL
tumor	NULL
cell	NULL
growth	NULL
,	NULL
thereby	NULL
preventing	NULL
the	NULL
outgrowth	NULL
of	NULL
escape	NULL
vari-ants	NULL
;	NULL
by	NULL
rendering	NULL
tumors	NULL
susceptible	NULL
to	NULL
NK	NULL
cell	NULL
attack	NULL
;	NULL
and	NULL
by	NULL
rendering	NULL
the	NULL
tumor	NULL
accessible	NULL
to	NULL
T	NULL
cells	NULL
as	NULL
the	NULL
tumor	NULL
begins	NULL
to	NULL
disintegrate	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
downregulates	NULL
VEGF	NULL
expression	NULL
,	NULL
and	NULL
reduces	NULL
vessel	NULL
density	NULL
HIF-1a	NULL
«	NULL
expression	NULL
was	NULL
detectable	NULL
throughout	NULL
tumors	NULL
0.4	NULL
cm	NULL
in	NULL
diameter	NULL
,	NULL
and	NULL
was	NULL
almost	NULL
completely	NULL
abrogated	NULL
by	NULL
antisense	NULL
HIF-l1	NULL
«	NULL
therapy	NULL
.	NULL

HIF-1	NULL
contributes	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
an	NULL
array	NULL
of	NULL
hypoxia-regulated	NULL
genes	NULL
including	NULL
those	NULL
for	NULL
VEGF	NULL
,	NULL
erythropoietin	NULL
,	NULL
and	NULL
those	NULL
of	NULL
the	NULL
glycolytic	NULL
pathway	NULL
including	NULL
lactate	NULL
dehydrogenase	NULL
A	NULL
,	NULL
pyruv-ate	NULL
kinase	NULL
M	NULL
,	NULL
enolase	NULL
1	NULL
,	NULL
phosphoglycerate	NULL
kinase	NULL
1	NULL
,	NULL
aldolase	NULL
A	NULL
,	NULL
phosphofructokinase	NULL
L	NULL
,	NULL
and	NULL
glucose	NULL
transporter-1	NULL
.	NULL

``	NULL
-	NULL
!	NULL

4	NULL
We	NULL
analyzed	NULL
VEGF	NULL
expression	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
activation	NULL
of	NULL
HIF-1-dependent	NULL
gene	NULL
expression	NULL
was	NULL
also	NULL
abolished	NULL
by	NULL
antisense	NULL
HIF-l	NULL
«	NULL
therapy	NULL
.	NULL

VEGF	NULL
is	NULL
a	NULL
potent	NULL
endothelial	NULL
mitogen	NULL
and	NULL
permeability	NULL
factor	NULL
,	NULL
commonly	NULL
expressed	NULL
in	NULL
tumors	NULL
,	NULL
and	NULL
has	NULL
been	NULL
implicated	NULL
in	NULL
both	NULL
physiologically	NULL
and	NULL
pathologically	NULL
occurring	NULL
angiogenesis	NULL
.	NULL
``	NULL

A	NULL
critical	NULL
role	NULL
for	NULL
VEGF	NULL
in	NULL
tumor	NULL
growth	NULL
has	NULL
been	NULL
suggested	NULL
by	NULL
the	NULL
inhibition	NULL
of	NULL
VEGF-induced	NULL
tumor	NULL
growth	NULL
by	NULL
blocking	NULL
antibodies	NULL
,	NULL
*	NULL
by	NULL
administration	NULL
of	NULL
antisense	NULL
VEGF	NULL
mRNAs	NULL
,	NULL
*	NULL
``	NULL
and	NULL
by	NULL
a	NULL
retrovirus	NULL
encoding	NULL
a	NULL
soluble	NULL
mutant	NULL
form	NULL
of	NULL
the	NULL
VEGF	NULL
receptor	NULL
.	NULL
``	NULL

Gene	NULL
transfer	NULL
of	NULL
antisense	NULL
HIF-1	NULL
«	NULL
down-regulated	NULL
the	NULL
expression	NULL
of	NULL
VEGF	NULL
,	NULL
and	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
new	NULL
blood	NULL
vessels	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
a	NULL
reduction	NULL
in	NULL
blood	NULL
vessel	NULL
density	NULL
.	NULL

Blood	NULL
vessels	NULL
in	NULL
control	NULL
tumors	NULL
appeared	NULL
larger	NULL
and	NULL
more	NULL
mature	NULL
than	NULL
those	NULL
in	NULL
tumors	NULL
treated	NULL
with	NULL
antisense	NULL
HIF-la	NULL
«	NULL
,	NULL
suggesting	NULL
that	NULL
blockade	NULL
of	NULL
HIF-1	NULL
also	NULL
impairs	NULL
the	NULL
maturation	NULL
and/or	NULL
patency	NULL
of	NULL
blood	NULL
vessels	NULL
.	NULL

Although	NULL
HIF-1	NULL
is	NULL
arguably	NULL
the	NULL
most	NULL
important	NULL
signalling	NULL
pathway	NULL
for	NULL
tumor	NULL
survival	NULL
under	NULL
hypoxia	NULL
,	NULL
other	NULL
pathways	NULL
are	NULL
also	NULL
activated	NULL
by	NULL
oncogenes	NULL
or	NULL
stress	NULL
.	NULL

Combination	NULL
therapy	NULL
that	NULL
combines	NULL
a	NULL
vascular	NULL
attack	NULL
with	NULL
immunotherapy	NULL
,	NULL
and	NULL
simultaneously	NULL
targets	NULL
other	NULL
tumor	NULL
survival	NULL
pathways	NULL
will	NULL
be	NULL
the	NULL
focus	NULL
of	NULL
future	NULL
investi-gations	NULL
.	NULL

Material	NULL
and	NULL
methods	NULL
Mice	NULL
and	NULL
cell	NULL
lines	NULL
Male	NULL
C57BL/6	NULL
mice	NULL
,	NULL
6-8	NULL
weeks	NULL
old	NULL
,	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
Animal	NULL
Resource	NULL
Unit	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
and	NULL
Health	NULL
Science	NULL
,	NULL
University	NULL
of	NULL
Auckland	NULL
,	NULL
Auckland	NULL
,	NULL
New	NULL
Zealand	NULL
.	NULL

The	NULL
EL-4	NULL
thymic	NULL
T	NULL
cell	NULL
lymphoma	NULL
,	NULL
which	NULL
is	NULL
of	NULL
C57BL/6	NULL
(	NULL
H-2b	NULL
)	NULL
origin	NULL
,	NULL
was	NULL
purchased	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

It	NULL
was	NULL
cultured	NULL
at	NULL
37°C	NULL
in	NULL
DMEM	NULL
medium	NULL
(	NULL
Gibco	NULL
BRL	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
50	NULL
U/ml	NULL
penicillin/streptomycin	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
1	NULL
mm	NULL
pyruvate	NULL
.	NULL

Expression	NULL
plasmids	NULL
A	NULL
320-bp	NULL
cDNA	NULL
fragment	NULL
encoding	NULL
the	NULL
5'-end	NULL
of	NULL
HIF-l1a	NULL
(	NULL
nucleotides	NULL
152	NULL
to	NULL
454	NULL
;	NULL
GenBank	NULL
AFOO03698	NULL
)	NULL
was	NULL
produced	NULL
through	NULL
PCR	NULL
using	NULL
the	NULL
IMAGE	NULL
clone	NULL
851237	NULL
as	NULL
a	NULL
template	NULL
,	NULL
and	NULL
the	NULL
two	NULL
primers	NULL
(	NULL
5	NULL
GGG	NULL
GAT	NULL
CCT	NULL
CTG	NULL
GAC	NULL
TTG	NULL
TCT	NULL
CTT	NULL
TC3	NULL
and	NULL
5	NULL
GGG	NULL
CTC	NULL
GAG	NULL
TAA	NULL
CTG	NULL
ATG	NULL
GTG	NULL
AGC	NULL
CTC	NULL
3	NULL
)	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
cloned	NULL
into	NULL
pGEMT	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
and	NULL
then	NULL
subcloned	NULL
into	NULL
peDNA3	NULL
(	NULL
Invitrogen	NULL
,	NULL
Carlsbad	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
at	NULL
BamHI	NULL
and	NULL
Xhol	NULL
sites	NULL
in	NULL
sense	NULL
orientation	NULL
,	NULL
and	NULL
into	NULL
peDNA3B	NULL
at	NULL
Xhol	NULL
and	NULL
BamHI	NULL
sites	NULL
in	NULL
an	NULL
antisense	NULL
orientation	NULL
.	NULL

The	NULL
peDNA3B	NULL
expression	NULL
vector	NULL
is	NULL
identical	NULL
to	NULL
peDNA3	NULL
,	NULL
except	NULL
the	NULL
polylinker	NULL
is	NULL
reversed	NULL
(	NULL
Lehnert	NULL
et	NULL
al	NULL
,	NULL
unpublished	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
plasmid	NULL
B7-1-pCDMS	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
1.2	NULL
kb	NULL
cDNA	NULL
fragment	NULL
encoding	NULL
full-length	NULL
mouse	NULL
B7-1	NULL
was	NULL
constructed	NULL
from	NULL
a	NULL
cDNA	NULL
clone	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
P	NULL
Linsley	NULL
,	NULL
Bristol-Myers-Squibb	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
,	NULL
USA	NULL
.	NULL

Gene	NULL
transfer	NULL
of	NULL
expression	NULL
plasmids	NULL
and	NULL
measurement	NULL
of	NULL
antitumor	NULL
activity	NULL
Purified	NULL
plasmids	NULL
were	NULL
diluted	NULL
in	NULL
a	NULL
solution	NULL
of	NULL
5	NULL
%	NULL
glucose	NULL
in	NULL
0.01	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
mixed	NULL
in	NULL
a	NULL
ratio	NULL
of	NULL
1:3	NULL
(	NULL
wtwt	NULL
)	NULL
with	NULL
DOTAP	NULL
cationic	NULL
liposomes	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
which	NULL
is	NULL
an	NULL
efficient	NULL
transfection	NULL
vehicle	NULL
.	NULL
``	NULL

Final	NULL
plasmid	NULL
concentration	NULL
was	NULL
1	NULL
mg/ml	NULL
.	NULL

Tumors	NULL
were	NULL
established	NULL
by	NULL
injection	NULL
of	NULL
2	NULL
x	NULL
10°	NULL
EL-4	NULL
tumor	NULL
cells	NULL
into	NULL
the	NULL
right	NULL
flank	NULL
of	NULL
mice	NULL
,	NULL
and	NULL
growth	NULL
determined	NULL
by	NULL
measuring	NULL
two	NULL
perpendicular	NULL
diameters	NULL
.	NULL

Animals	NULL
were	NULL
killed	NULL
when	NULL
tumors	NULL
reached	NULL
more	NULL
than	NULL
1	NULL
cm	NULL
in	NULL
diameter	NULL
,	NULL
in	NULL
accord	NULL
with	NULL
Animal	NULL
Ethics	NULL
Approval	NULL
(	NULL
University	NULL
of	NULL
Auckland	NULL
)	NULL
.	NULL

Tumors	NULL
reached	NULL
0.1	NULL
and	NULL
0.4	NULL
cm	NULL
in	NULL
diameter	NULL
after	NULL
approximately	NULL
14-18	NULL
days	NULL
,	NULL
and	NULL
were	NULL
injected	NULL
with	NULL
100	NULL
pl	NULL
expression	NULL
plasmid	NULL
(	NULL
100	NULL
ug	NULL
)	NULL
.	NULL

For	NULL
combinational	NULL
treatment	NULL
,	NULL
reagents	NULL
were	NULL
delivered	NULL
in	NULL
a	NULL
timed	NULL
fashion	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
.	NULL
``	NULL

Thus	NULL
,	NULL
B7-1	NULL
cDNA	NULL
was	NULL
injected	NULL
first	NULL
,	NULL
followed	NULL
by	NULL
antisense	NULL
HIF-l	NULL
«	NULL
cDNA	NULL
48	NULL
h	NULL
later	NULL
.	NULL

Empty	NULL
vectors	NULL
served	NULL
as	NULL
control	NULL
reagents	NULL
.	NULL

Cured	NULL
mice	NULL
were	NULL
rechallenged	NULL
3	NULL
weeks	NULL
after	NULL
the	NULL
disappearance	NULL
of	NULL
tumors	NULL
by	NULL
injecting	NULL
1	NULL
x	NULL
10°	NULL
EL-4	NULL
cells	NULL
subcutaneously	NULL
into	NULL
the	NULL
opposing	NULL
flank	NULL
(	NULL
left	NULL
flank	NULL
)	NULL
.	NULL

All	NULL
experiments	NULL
included	NULL
six	NULL
mice	NULL
per	NULL
group	NULL
,	NULL
and	NULL
each	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
once	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
Immunohistochemistry	NULL
Tumor	NULL
cryosections	NULL
(	NULL
10	NULL
um	NULL
)	NULL
were	NULL
prepared	NULL
2	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
,	NULL
treated	NULL
with	NULL
acetone	NULL
,	NULL
rinsed	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
blocked	NULL
with	NULL
2	NULL
%	NULL
BSA	NULL
for	NULL
2	NULL
h.	NULL
The	NULL
sections	NULL
underwent	NULL
a	NULL
overnight	NULL
incubation	NULL
with	NULL
either	NULL
a	NULL
hamster	NULL
anti-B7-1	NULL
mAb	NULL
(	NULL
1610	NULL
,	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
mouse	NULL
anti-mouse	NULL
HIF-1	NULL
«	NULL
mAb	NULL
(	NULL
H1	NULL
«	NULL
67	NULL
,	NULL
Novus	NULL
Biologi-cals	NULL
,	NULL
Littleton	NULL
,	NULL
CO	NULL
,	NULL
USA	NULL
)	NULL
,	NULL
or	NULL
rabbit	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
VEGF	NULL
(	NULL
Ab-1	NULL
,	NULL
Lab	NULL
Vision	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

They	NULL
were	NULL
subsequently	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
appropriate	NULL
secondary	NULL
antibodies	NULL
,	NULL
using	NULL
the	NULL
VECTASTAIN	NULL
Universal	NULL
Quick	NULL
kit	NULL
(	NULL
Vector	NULL
Laboratories	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
;	NULL
and	NULL
developed	NULL
with	NULL
Sigma	NULL
FAST	NULL
DAB	NULL
(	NULL
3,3'-diaminoben-zidine	NULL
tetrahydrochloride	NULL
)	NULL
and	NULL
COCI	NULL
,	NULL
enhancer	NULL
tablets	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Sections	NULL
were	NULL
counterstained	NULL
with	NULL
Mayer	NULL
's	NULL
hematoxylin	NULL
,	NULL
mounted	NULL
and	NULL
examined	NULL
by	NULL
microscopy	NULL
.	NULL

Assessment	NULL
of	NULL
vascularity	NULL
Sections	NULL
(	NULL
10	NULL
um	NULL
)	NULL
were	NULL
cut	NULL
from	NULL
fresh	NULL
frozen	NULL
tumors	NULL
4	NULL
days	NULL
following	NULL
gene	NULL
transfer	NULL
.	NULL

Slides	NULL
were	NULL
immunostained	NULL
with	NULL
the	NULL
anti-CD31	NULL
antibody	NULL
,	NULL
MEC13.3	NULL
(	NULL
Pharmingen	NULL
)	NULL
,	NULL
as	NULL
above	NULL
.	NULL

The	NULL
method	NULL
for	NULL
assessment	NULL
of	NULL
blood	NULL
vessel	NULL
density	NULL
was	NULL
as	NULL
described	NULL
.	NULL
``	NULL

Briefly	NULL
,	NULL
40x	NULL
high	NULL
power	NULL
magnification	NULL
fields	NULL
(	NULL
0.155	NULL
mm	NULL
)	NULL
were	NULL
blindly	NULL
and	NULL
randomly	NULL
chosen	NULL
for	NULL
blood	NULL
vessel	NULL
counts	NULL
.	NULL

Blood	NULL
vessels	NULL
stained	NULL
with	NULL
anti-CD31	NULL
mAb	NULL
were	NULL
recorded	NULL
for	NULL
five	NULL
fields	NULL
,	NULL
and	NULL
the	NULL
mean	NULL
of	NULL
the	NULL
highest	NULL
three	NULL
counts	NULL
per	NULL
surface	NULL
area	NULL
(	NULL
0.155	NULL
mm	NULL
)	NULL
was	NULL
calculated	NULL
.	NULL

The	NULL
concentric	NULL
circles	NULL
method*~	NULL
was	NULL
used	NULL
to	NULL
assess	NULL
vascularity	NULL
.	NULL

Western	NULL
blotting	NULL
Tumors	NULL
previously	NULL
injected	NULL
with	NULL
anti-sense	NULL
HIF-1	NULL
«	NULL
,	NULL
sense	NULL
HIF-l	NULL
«	NULL
,	NULL
or	NULL
empty	NULL
plasmid	NULL
were	NULL
excised	NULL
,	NULL
and	NULL
homogenized	NULL
in	NULL
lysate	NULL
buffer	NULL
(	NULL
50	NULL
mmol/l	NULL
Tris	NULL
pH	NULL
7.4	NULL
,	NULL
100	NULL
mol/l	NULL
EDTA	NULL
,	NULL
0.25	NULL
mol/l	NULL
sucrose	NULL
,	NULL
1	NULL
%	NULL
SDS	NULL
,	NULL
1	NULL
%	NULL
NP40	NULL
,	NULL
1	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
1umg/ml	NULL
pepstatin	NULL
A	NULL
and	NULL
100	NULL
mol/l	NULL
phenyImethylsulfonylfluoride	NULL
)	NULL
at	NULL
4°C	NULL
using	NULL
a	NULL
motor-driven	NULL
Virtus	NULL
homogenizer	NULL
(	NULL
Virtus	NULL
,	NULL
Gardiner	NULL
,	NULL
NY	NULL
,	NULL
USA	NULL
)	NULL
.	NULL

Tumor	NULL
lysates	NULL
from	NULL
each	NULL
group	NULL
of	NULL
mice	NULL
were	NULL
pooled	NULL
,	NULL
and	NULL
cell	NULL
debris	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
10	NULL
000	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Samples	NULL
containing	NULL
100	NULL
ug	NULL
protein	NULL
per	NULL
well	NULL
were	NULL
resolved	NULL
on	NULL
10	NULL
%	NULL
polyacrylamide	NULL
SDS	NULL
gels	NULL
under	NULL
reducing	NULL
conditions	NULL
,	NULL
and	NULL
electrophoretically	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Hybond	NULL
C	NULL
extra	NULL
;	NULL
Amersham	NULL
Life	NULL
Science	NULL
Buckinghamshire	NULL
,	NULL
UK	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
stained	NULL
with	NULL
Ponceau	NULL
S	NULL
to	NULL
ensure	NULL
correct	NULL
transfer	NULL
of	NULL
proteins	NULL
.	NULL

After	NULL
blocking	NULL
the	NULL
membranes	NULL
with	NULL
3	NULL
%	NULL
BSA	NULL
in	NULL
TBS-T	NULL
(	NULL
20	NULL
mmol/l	NULL
Tris	NULL
,	NULL
137	NULL
mmol/l	NULL
NaCl	NULL
pH	NULL
7.6	NULL
containing	NULL
0.1	NULL
%	NULL
Tween-20	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
blots	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
anti-mouse	NULL
HIF-l	NULL
«	NULL
mAb	NULL
(	NULL
H1	NULL
«	NULL
67	NULL
,	NULL
Novus	NULL
Biologicals	NULL
)	NULL
,	NULL
or	NULL
a	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
against	NULL
VEGF	NULL
(	NULL
Ab-1	NULL
,	NULL
Lab	NULL
Vision	NULL
)	NULL
.	NULL

The	NULL
membranes	NULL
were	NULL
subsequently	NULL
incubated	NULL
with	NULL
horseradish	NULL
peroxi-dase-conjugated	NULL
secondary	NULL
antibodies	NULL
,	NULL
and	NULL
immuno-reactivity	NULL
detected	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
Amersham	NULL
)	NULL
,	NULL
and	NULL
exposure	NULL
to	NULL
X-ray	NULL
film	NULL
.	NULL

Depletion	NULL
of	NULL
leukocyte	NULL
subsets	NULL
Mice	NULL
were	NULL
depleted	NULL
of	NULL
CD8+*	NULL
and	NULL
CD4*	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
NK	NULL
cells	NULL
by	NULL
i.p	NULL
.	NULL

and	NULL
i.v	NULL
.	NULL

injection	NULL
4	NULL
days	NULL
before	NULL
gene	NULL
transfer	NULL
,	NULL
and	NULL
thereafter	NULL
every	NULL
alternate	NULL
day	NULL
with	NULL
300	NULL
ug	NULL
(	NULL
0.1	NULL
ml	NULL
)	NULL
of	NULL
the	NULL
53-6.72	NULL
(	NULL
anti-CD8	NULL
)	NULL
,	NULL
GKk1.5	NULL
(	NULL
anti-CD4	NULL
)	NULL
,	NULL
and	NULL
PK136	NULL
(	NULL
anti-NK	NULL
)	NULL
mAbs	NULL
.	NULL

Rat	NULL
IgG	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
antibody	NULL
.	NULL

Antibodies	NULL
were	NULL
ammonium	NULL
sulphate	NULL
fractions	NULL
of	NULL
ascites	NULL
,	NULL
which	NULL
titered	NULL
to	NULL
at	NULL
least	NULL
1:2000	NULL
by	NULL
FACS	NULL
643	NULL
Gene	NULL
Therapy	NULL
Antisense	NULL
HIF-L1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
644	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
,	NULL
USA	NULL
)	NULL
staining	NULL
of	NULL
spleno-cytes	NULL
.	NULL

Depletion	NULL
of	NULL
individual	NULL
leukocyte	NULL
subsets	NULL
was	NULL
found	NULL
to	NULL
be	NULL
more	NULL
than	NULL
90	NULL
%	NULL
effective	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
FACScan	NULL
analysis	NULL
.	NULL

Statistical	NULL
analysis	NULL
Results	NULL
were	NULL
expressed	NULL
as	NULL
mean	NULL
values	NULL
+	NULL
standard	NULL
deviation	NULL
(	NULL
s.d	NULL
.	NULL
)	NULL

,	NULL
and	NULL
a	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
was	NULL
used	NULL
for	NULL
evaluating	NULL
statistical	NULL
significance	NULL
.	NULL

A	NULL
value	NULL
of	NULL
P	NULL
<	NULL
0.05	NULL
was	NULL
used	NULL
for	NULL
statistical	NULL
significance	NULL
.	NULL

Acknowledgements	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
World	NULL
Health	NULL
Organization	NULL
,	NULL
the	NULL
Royal	NULL
Society	NULL
of	NULL
New	NULL
Zealand	NULL
,	NULL
the	NULL
Wellcome	NULL
Trust	NULL
(	NULL
UK	NULL
)	NULL
,	NULL
the	NULL
Cancer	NULL
Society	NULL
of	NULL
New	NULL
Zealand	NULL
,	NULL
the	NULL
Health	NULL
Research	NULL
Council	NULL
of	NULL
New	NULL
Zealand	NULL
,	NULL
the	NULL
Lottery	NULL
Grants	NULL
Board	NULL
of	NULL
New	NULL
Zealand	NULL
,	NULL
and	NULL
the	NULL
Maurice	NULL
and	NULL
Phyllis	NULL
Paykel	NULL
Trust	NULL
.	NULL

We	NULL
thank	NULL
Ms	NULL
Joanna	NULL
Stewart	NULL
(	NULL
Community	NULL
Health	NULL
Department	NULL
,	NULL
University	NULL
of	NULL
Auckland	NULL
)	NULL
for	NULL
help	NULL
with	NULL
statistical	NULL
analyses	NULL
.	NULL

References	NULL
1	NULL
Hockel	NULL
M	NULL
et	NULL
al	NULL
.	NULL

Association	NULL
between	NULL
tumor	NULL
hypoxia	NULL
and	NULL
malignant	NULL
progression	NULL
in	NULL
advanced	NULL
cancer	NULL
of	NULL
the	NULL
uterine	NULL
cervix	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56	NULL
:	NULL
4509-4515	NULL
.	NULL

2	NULL
Blancher	NULL
C	NULL
,	NULL
Harris	NULL
AL	NULL
.	NULL

The	NULL
molecular	NULL
basis	NULL
of	NULL
the	NULL
hypoxia	NULL
response	NULL
pathway	NULL
:	NULL
tumor	NULL
hypoxia	NULL
as	NULL
a	NULL
therapy	NULL
target	NULL
.	NULL

Cancer	NULL
Metast	NULL
Rev	NULL
1998	NULL
;	NULL
17	NULL
:	NULL
187-194	NULL
.	NULL

3	NULL
Hanahan	NULL
D	NULL
,	NULL
Folkman	NULL
J	NULL
.	NULL

Patterns	NULL
and	NULL
emerging	NULL
mechanisms	NULL
of	NULL
the	NULL
angiogenic	NULL
switch	NULL
during	NULL
tumorigenesis	NULL
.	NULL

Cell	NULL
1996	NULL
;	NULL
86	NULL
:	NULL
353-364	NULL
.	NULL

4	NULL
Brizel	NULL
DM	NULL
et	NULL
al	NULL
.	NULL

Tumor	NULL
oxygenation	NULL
predicts	NULL
the	NULL
likelihood	NULL
of	NULL
distant	NULL
metastases	NULL
in	NULL
human	NULL
soft	NULL
tissue	NULL
sarcoma	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56	NULL
:	NULL
941-943	NULL
.	NULL

5	NULL
Nordsmark	NULL
M	NULL
,	NULL
Overgaard	NULL
M	NULL
,	NULL
Overgaard	NULL
J.	NULL
Pretreatment	NULL
oxygenation	NULL
predicts	NULL
radiation	NULL
response	NULL
in	NULL
advanced	NULL
squamous	NULL
cell	NULL
carcinoma	NULL
of	NULL
the	NULL
head	NULL
and	NULL
neck	NULL
.	NULL

Radiother	NULL
Oncol	NULL
1996	NULL
;	NULL
41	NULL
:	NULL
31-39	NULL
.	NULL

6	NULL
Semenza	NULL
GL	NULL
,	NULL
Wang	NULL
GL	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
induced	NULL
by	NULL
hypoxia	NULL
via	NULL
de	NULL
novo	NULL
protein	NULL
synthesis	NULL
binds	NULL
to	NULL
the	NULL
human	NULL
erythropoietin	NULL
gene	NULL
enhancer	NULL
at	NULL
a	NULL
site	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
Cell	NULL
Biol	NULL
1992	NULL
;	NULL
12	NULL
:	NULL
5447-5454	NULL
.	NULL

7	NULL
Maxwell	NULL
PH	NULL
,	NULL
Pugh	NULL
CW	NULL
,	NULL
Ratcliffe	NULL
PJ	NULL
.	NULL

Inducible	NULL
operation	NULL
of	NULL
the	NULL
erythropoietin	NULL
3	NULL
'	NULL
enhancer	NULL
in	NULL
multiple	NULL
cell	NULL
lines	NULL
:	NULL
evidence	NULL
for	NULL
a	NULL
widespread	NULL
oxygen-sensing	NULL
mechanism	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1993	NULL
;	NULL
90	NULL
:	NULL
2423-2427	NULL
.	NULL

8	NULL
Bunn	NULL
HF	NULL
,	NULL
Poyton	NULL
RO	NULL
.	NULL

Oxygen	NULL
sensing	NULL
and	NULL
molecular	NULL
adaption	NULL
to	NULL
hypoxia	NULL
.	NULL

Physiol	NULL
Rev	NULL
1996	NULL
;	NULL
76	NULL
:	NULL
839-885	NULL
.	NULL

9	NULL
Wang	NULL
GL	NULL
,	NULL
Semenza	NULL
GL	NULL
.	NULL

General	NULL
involvement	NULL
of	NULL
hypoxia-inducible	NULL
factor-1	NULL
in	NULL
transcriptional	NULL
response	NULL
to	NULL
hypoxia	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1993	NULL
;	NULL
90	NULL
:	NULL
4304-4308	NULL
.	NULL

10	NULL
Wang	NULL
GL	NULL
,	NULL
Jiang	NULL
B-H	NULL
,	NULL
Rue	NULL
EA	NULL
,	NULL
Semenza	NULL
GL	NULL
.	NULL

Hypoxia-inducible	NULL
factor	NULL
1	NULL
is	NULL
a	NULL
basic	NULL
helix-loop-helix	NULL
PAS	NULL
heterodimer	NULL
regulated	NULL
by	NULL
cellular	NULL
O	NULL
;	NULL
tension	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1995	NULL
;	NULL
92	NULL
:	NULL
5510-5514	NULL
.	NULL

11	NULL
Jiang	NULL
BH	NULL
et	NULL
al	NULL
.	NULL

Dimerization	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
and	NULL
transactivation	NULL
properties	NULL
of	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1996	NULL
;	NULL
271	NULL
:	NULL
17771-17778	NULL
.	NULL

12	NULL
Ratcliffe	NULL
PJ	NULL
,	NULL
O'Rourke	NULL
JF	NULL
,	NULL
Maxwell	NULL
PH	NULL
,	NULL
Pugh	NULL
CW	NULL
.	NULL

Oxygen	NULL
sens-ing	NULL
,	NULL
hypoxia-inducible	NULL
factor-1	NULL
and	NULL
the	NULL
regulation	NULL
of	NULL
mammalian	NULL
gene	NULL
expression	NULL
.	NULL

J	NULL
Exp	NULL
Biol	NULL
1998	NULL
;	NULL
201	NULL
:	NULL
1153-1162	NULL
.	NULL

13	NULL
Semenza	NULL
GL	NULL
et	NULL
al	NULL
.	NULL

Hypoxia	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
aldolase	NULL
A	NULL
,	NULL
enolase	NULL
1	NULL
,	NULL
and	NULL
lactate	NULL
dehydrogenase	NULL
A	NULL
gene	NULL
promoters	NULL
contain	NULL
essential	NULL
binding	NULL
sites	NULL
for	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1996	NULL
;	NULL
271	NULL
:	NULL
32529-32537	NULL
.	NULL

14	NULL
Dachs	NULL
GU	NULL
,	NULL
Stratford	NULL
IJ	NULL
.	NULL

The	NULL
molecular	NULL
response	NULL
of	NULL
mammalian	NULL
cells	NULL
to	NULL
hypoxia	NULL
and	NULL
the	NULL
potential	NULL
for	NULL
exploitation	NULL
in	NULL
cancer	NULL
therapy	NULL
.	NULL

Br	NULL
J	NULL
Cancer	NULL
1996	NULL
;	NULL
74	NULL
;	NULL
$	NULL
126-5132	NULL
.	NULL

Gene	NULL
Therapy	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
30	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
37	NULL
38	NULL
Ryan	NULL
HE	NULL
,	NULL
Lo	NULL
J	NULL
,	NULL
Johnson	NULL
RS	NULL
.	NULL

HIF-l	NULL
«	NULL
is	NULL
required	NULL
for	NULL
solid	NULL
tumor	NULL
formation	NULL
and	NULL
embryonic	NULL
vascularization	NULL
.	NULL

EMBO	NULL
J	NULL
1998	NULL
;	NULL
17	NULL
:	NULL
3005-3015	NULL
.	NULL

Iyer	NULL
NV	NULL
et	NULL
al	NULL
.	NULL

Cellular	NULL
and	NULL
developmental	NULL
control	NULL
of	NULL
O	NULL
,	NULL
homeo-stasis	NULL
by	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
«	NULL
.	NULL

Genes	NULL
Dev	NULL
1998	NULL
;	NULL
12	NULL
;	NULL
149-162	NULL
.	NULL

Zhong	NULL
H	NULL
et	NULL
al	NULL
.	NULL

Overexpression	NULL
of	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
«	NULL
in	NULL
common	NULL
human	NULL
cancers	NULL
and	NULL
their	NULL
metastases	NULL
.	NULL

Cancer	NULL
Res	NULL
1999	NULL
;	NULL
59	NULL
:	NULL
5830-5835	NULL
.	NULL

Kallio	NULL
PJ	NULL
et	NULL
al	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
hypoxia-inducible	NULL
transcription	NULL
factor	NULL
1	NULL
«	NULL
by	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1999	NULL
;	NULL
274	NULL
:	NULL
6519-6525	NULL
.	NULL

Huang	NULL
LE	NULL
,	NULL
Gu	NULL
J	NULL
,	NULL
Scha	NULL
M	NULL
,	NULL
Bunn	NULL
HF	NULL
.	NULL

Regulation	NULL
of	NULL
hypoxia-inducible	NULL
factor	NULL
1	NULL
«	NULL
is	NULL
mediated	NULL
by	NULL
an	NULL
O	NULL
,	NULL
-dependent	NULL
degradation	NULL
domain	NULL
via	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1998	NULL
;	NULL
95	NULL
:	NULL
7987-7992	NULL
.	NULL

Latif	NULL
F	NULL
et	NULL
al	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
von	NULL
Hippel-Lindau	NULL
disease	NULL
tumor	NULL
suppressor	NULL
gene	NULL
.	NULL

Science	NULL
1993	NULL
;	NULL
260	NULL
:	NULL
1317-1320	NULL
.	NULL

Maxwell	NULL
PH	NULL
et	NULL
al	NULL
.	NULL

The	NULL
tumor	NULL
suppressor	NULL
protein	NULL
VHL	NULL
targets	NULL
hypoxia-inducible	NULL
factors	NULL
for	NULL
oxygen-dependent	NULL
proteolysis	NULL
.	NULL

Nature	NULL
1999	NULL
;	NULL
399	NULL
:	NULL
271-275	NULL
.	NULL

Scheibel	NULL
T	NULL
,	NULL
Buchner	NULL
,	NULL
J	NULL
.	NULL

The	NULL
Hsp90	NULL
complex-a	NULL
super-chaperone	NULL
machine	NULL
as	NULL
a	NULL
novel	NULL
drug	NULL
target	NULL
.	NULL

Biochem	NULL
Pharmacol	NULL
1998	NULL
;	NULL
56	NULL
:	NULL
675-682	NULL
.	NULL

Minet	NULL
E	NULL
et	NULL
al	NULL
.	NULL

Hypoxia-induced	NULL
activation	NULL
of	NULL
HIF-1	NULL
:	NULL
role	NULL
of	NULL
HIF-1	NULL
alpha-Hsp90	NULL
interaction	NULL
.	NULL

FEBS	NULL
Lett	NULL
1999	NULL
;	NULL
460	NULL
:	NULL
251-256	NULL
.	NULL

Iliopoulos	NULL
O	NULL
ef	NULL
al	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
hypoxia-inducible	NULL
genes	NULL
by	NULL
the	NULL
von	NULL
Hippel-Lindau	NULL
protein	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1996	NULL
;	NULL
93	NULL
:	NULL
10595-10599	NULL
.	NULL

Kaelin	NULL
WG	NULL
,	NULL
Maher	NULL
ER	NULL
.	NULL

The	NULL
VHL	NULL
tumor-suppressor	NULL
gene	NULL
para-digm	NULL
.	NULL

Trends	NULL
Genet	NULL
1998	NULL
;	NULL
14	NULL
:	NULL
423-426	NULL
.	NULL

Kim	NULL
K	NULL
]	NULL
ef	NULL
al	NULL
.	NULL

Inhibition	NULL
of	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor-induced	NULL
angiogenesis	NULL
suppresses	NULL
tumor	NULL
growth	NULL
in	NULL
vivo	NULL
.	NULL

Nature	NULL
1993	NULL
;	NULL
362	NULL
:	NULL
841-844	NULL
.	NULL

Warren	NULL
RS	NULL
et	NULL
al	NULL
.	NULL

Regulation	NULL
by	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor	NULL
of	NULL
human	NULL
colon	NULL
cancer	NULL
tumorigenesis	NULL
in	NULL
a	NULL
mouse	NULL
model	NULL
of	NULL
experimental	NULL
liver	NULL
metastasis	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1995	NULL
;	NULL
95	NULL
:	NULL
1789-1797	NULL
.	NULL

Cheng	NULL
S-Y	NULL
et	NULL
al	NULL
.	NULL

Suppression	NULL
of	NULL
glioblastoma	NULL
angiogenicity	NULL
and	NULL
tumorigenicity	NULL
by	NULL
inhibition	NULL
of	NULL
endogenous	NULL
expression	NULL
of	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1996	NULL
;	NULL
93	NULL
:	NULL
8502-8507	NULL
.	NULL

Kanwar	NULL
JR	NULL
et	NULL
al	NULL
.	NULL

Vascular	NULL
attack	NULL
by	NULL
5,6-dimethylxanthenone-4-acetic	NULL
acid	NULL
combined	NULL
with	NULL
B7.1-mediated	NULL
immunotherapy	NULL
overcomes	NULL
immune-resistance	NULL
and	NULL
leads	NULL
to	NULL
the	NULL
eradication	NULL
of	NULL
large	NULL
tumors	NULL
.	NULL

Cancer	NULL
Res	NULL
(	NULL
in	NULL
press	NULL
)	NULL
.	NULL

Kanwar	NULL
J	NULL
,	NULL
Berg	NULL
R	NULL
,	NULL
Lehnert	NULL
K	NULL
,	NULL
Krissansen	NULL
GW	NULL
.	NULL

Taking	NULL
lessons	NULL
from	NULL
dendritic	NULL
cells	NULL
:	NULL
multiple	NULL
xenogeneic	NULL
ligands	NULL
for	NULL
leukocyte	NULL
integrins	NULL
have	NULL
the	NULL
potential	NULL
to	NULL
stimulate	NULL
anti-tumor	NULL
immunity	NULL
.	NULL

Gene	NULL
Therapy	NULL
1999	NULL
;	NULL
6	NULL
:	NULL
1835-1844	NULL
.	NULL

Townsend	NULL
SE	NULL
,	NULL
Allison	NULL
JP	NULL
.	NULL

Tumor	NULL
rejection	NULL
after	NULL
direct	NULL
costimulation	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
by	NULL
B7-transfected	NULL
melanoma	NULL
cells	NULL
.	NULL

Science	NULL
1993	NULL
;	NULL
259	NULL
:	NULL
638-370	NULL
.	NULL

Chen	NULL
L	NULL
et	NULL
al	NULL
.	NULL

Costimulation	NULL
of	NULL
anti-tumor	NULL
immunity	NULL
by	NULL
the	NULL
B7	NULL
counterreceptor	NULL
for	NULL
the	NULL
T	NULL
lymphocyte	NULL
molecules	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
.	NULL

Cell	NULL
1992	NULL
;	NULL
71	NULL
:	NULL
1093-1102	NULL
.	NULL

Pedley	NULL
RB	NULL
et	NULL
al	NULL
.	NULL

Ablation	NULL
of	NULL
colorectal	NULL
xenografts	NULL
with	NULL
combined	NULL
radioimmunotherapy	NULL
and	NULL
tumor	NULL
blood	NULL
flow-modifying	NULL
agents	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56	NULL
:	NULL
3293-3300	NULL
.	NULL

Finlay	NULL
GJ	NULL
,	NULL
Ching	NULL
LM	NULL
,	NULL
Wilson	NULL
WR	NULL
,	NULL
Baguley	NULL
BC	NULL
.	NULL

Resistance	NULL
of	NULL
cultured	NULL
Lewis	NULL
lung	NULL
carcinoma	NULL
cell	NULL
lines	NULL
to	NULL
tiazofurin	NULL
.	NULL

J	NULL
Nat	NULL
!	NULL

Cancer	NULL
Inst	NULL
1987	NULL
;	NULL
79	NULL
:	NULL
291-296	NULL
.	NULL

Baguley	NULL
BC	NULL
,	NULL
Ching	NULL
LM	NULL
.	NULL

Immunomodulatory	NULL
actions	NULL
of	NULL
xan-thenone	NULL
anticancer	NULL
agents	NULL
.	NULL

BioDrugs	NULL
1997	NULL
;	NULL
8	NULL
:	NULL
119-127	NULL
.	NULL

Cao	NULL
Y	NULL
et	NULL
al	NULL
.	NULL

Expression	NULL
of	NULL
angiostatin	NULL
cDNA	NULL
in	NULL
a	NULL
murine	NULL
fibros-arcoma	NULL
suppresses	NULL
primary	NULL
tumor	NULL
growth	NULL
and	NULL
produces	NULL
long-term	NULL
dormancy	NULL
of	NULL
metastases	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1998	NULL
;	NULL
101	NULL
;	NULL
1055-1063	NULL
.	NULL

Boehm	NULL
T	NULL
,	NULL
Folkman	NULL
J	NULL
,	NULL
Browder	NULL
T	NULL
,	NULL
O'Reilly	NULL
MS.	NULL
Antiangiogenic	NULL
therapy	NULL
of	NULL
experimental	NULL
cancer	NULL
does	NULL
not	NULL
induce	NULL
acquired	NULL
drug	NULL
resistance	NULL
.	NULL

Nature	NULL
1997	NULL
;	NULL
390	NULL
:	NULL
404-407	NULL
.	NULL

Melder	NULL
RJ	NULL
et	NULL
al	NULL
.	NULL

During	NULL
angiogenesis	NULL
,	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor	NULL
and	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
regulate	NULL
natural	NULL
killer	NULL
cell	NULL
adhesion	NULL
to	NULL
tumor	NULL
endothelium	NULL
.	NULL

Nat	NULL
Med	NULL
1996	NULL
;	NULL
2	NULL
:	NULL
992-997	NULL
.	NULL

39	NULL
Ferrara	NULL
N	NULL
,	NULL
Houk	NULL
L	NULL
,	NULL
Jakeman	NULL
L	NULL
,	NULL
Leung	NULL
DW	NULL
.	NULL

Molecular	NULL
and	NULL
bio-	NULL
logical	NULL
properties	NULL
of	NULL
the	NULL
vascular	NULL
endothelial	NULL
cell	NULL
growth	NULL
factor	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

Endocr	NULL
Rev	NULL
1992	NULL
;	NULL
13	NULL
:	NULL
18-32	NULL
.	NULL

40	NULL
Borgstrom	NULL
P	NULL
,	NULL
Killan	NULL
KJ	NULL
,	NULL
Sriramarao	NULL
P	NULL
,	NULL
Ferrara	NULL
N.	NULL
Complete	NULL
inhi-	NULL
41	NULL
bition	NULL
of	NULL
angiogenesis	NULL
and	NULL
growth	NULL
of	NULL
microtumors	NULL
by	NULL
anti-vas-cular	NULL
endothelial	NULL
growth	NULL
factor	NULL
neutralizing	NULL
antibody	NULL
:	NULL
novel	NULL
concepts	NULL
of	NULL
angiostatic	NULL
therapy	NULL
from	NULL
intravital	NULL
video	NULL
microscopy	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56	NULL
:	NULL
4032-4039	NULL
.	NULL

Saleh	NULL
M	NULL
,	NULL
Stacker	NULL
SA	NULL
,	NULL
Wilks	NULL
AF	NULL
.	NULL

Inhibition	NULL
of	NULL
growth	NULL
of	NULL
C6	NULL
gli-oma	NULL
cells	NULL
in	NULL
vivo	NULL
by	NULL
expression	NULL
of	NULL
antisense	NULL
vascular	NULL
endothelial	NULL
growth	NULL
factor	NULL
sequence	NULL
.	NULL

Cancer	NULL
Res	NULL
1996	NULL
;	NULL
56	NULL
:	NULL
393-401	NULL
.	NULL

Antisense	NULL
HIF-1	NULL
«	NULL
enhances	NULL
cancer	NULL
immunotherapy	NULL
X	NULL
Sun	NULL
et	NULL
al	NULL
Cl	NULL
)	NULL
42	NULL
Millaruer	NULL
B	NULL
et	NULL
al	NULL
.	NULL

Glioblastoma	NULL
growth	NULL
inhibited	NULL
in	NULL
vivo	NULL
by	NULL
a	NULL
645	NULL
dominant-negative	NULL
Flk-1	NULL
mutant	NULL
.	NULL

Nature	NULL
1994	NULL
;	NULL
367	NULL
:	NULL
576-579	NULL
.	NULL

43	NULL
Kayar	NULL
SR	NULL
,	NULL
Archer	NULL
PG	NULL
,	NULL
Lechher	NULL
AJ	NULL
,	NULL
Banchero	NULL
N.	NULL
Evaluation	NULL
of	NULL
the	NULL
concentric	NULL
circles	NULL
method	NULL
for	NULL
estimating	NULL
capillary-tissue	NULL
diffusion	NULL
distances	NULL
.	NULL

Microvascular	NULL
Res	NULL
1982	NULL
;	NULL
24	NULL
:	NULL
342-353	NULL
.	NULL

44	NULL
Maxwell	NULL
PH	NULL
et	NULL
al	NULL
.	NULL

Hypoxia-inducible	NULL
factor-1	NULL
modulates	NULL
gene	NULL
expression	NULL
in	NULL
solid	NULL
tumors	NULL
and	NULL
influences	NULL
both	NULL
angiogenesis	NULL
and	NULL
tumor	NULL
growth	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1997	NULL
;	NULL
94	NULL
;	NULL
8104-8109	NULL
.	NULL

Gene	NULL
Therapy	NULL

